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Oxidative stress 
 
Living organisms continuously produce reactive species such as free radicals. Free 
radicals are molecules with one or more unpaired electrons in their outer orbital, 
which makes them very unstable and reactive towards other molecules to obtain a 
paired electron. Besides free radicals also reactive species that contain a paired 
electron are formed, e.g. peroxynitrite. All these reactive molecules are generally 
divided in reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
(Table 1) (Kohen and Nyska, 2002). 
 
Table 1. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
 Radicals Nonradicals 
ROS Superoxide, O2•- Hydrogen peroxide H2O2 
 Hydroxyl, OH• Hypochlorous acid, HOCl 
 Peroxyl, RO2• Ozone, O3 
 Alkoxyl, RO• Singlet oxygen, ǻg 
   
   
RNS Nitric oxide, NO• Nitrous acid, HNO2 
 Nitrogen dioxide, NO2• Dinitrogen tetroxide, N2O4 
  Dinitrogen trioxide, N2O3 
  Peroxynitrous acid, ONOOH 
  Nitronium cation, NO2+ 
  Alkyl peroxinitrites, ROONO 
 
ROS can be formed endogenously. The main source of ROS is aerobic respiration. 
Aerobic respiration requires oxygen in order to generate ATP. The process in which 
ATP is produced, called oxidative phosphorylation, involves electron transport. In 
this process oxygen is reduced to water, but 1 to 2 % of the oxygen is partly reduced 
(Magder, 2006). This leads to the formation of reactive species, especially 
superoxide anion (O2•-) and hydrogen peroxide (H2O2). In the presence of transition 
metal ions, the even more reactive hydroxyl radical (OH•) can be formed. Hydroxyl 
radicals react immediately with virtually any molecule it encounters. Most other 
radicals are less reactive and thus will react more selectively (Galli et al., 2005). 
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ROS are also produced by e.g. peroxisomal ȕ-oxidation of fatty acids and the 
cytochrome P450 system. There are also exogenous sources of radicals including 
ionizing radiation, ultraviolet light, toxins and cigarette smoke (Valko et al., 2007). 
ROS are involved in various physiological effects including cell to cell signaling, 
essential in maintaining homeostasis. In addition, ROS play a pivotal role in 
catalytic oxidation of some endogenous compounds and xenobiotics, maintain 
vascular tone and are part of the physiological host defense. Moreover, increased 
ROS production can induce cellular senescence and apoptosis which could protect 
against tumor genesis or uncontrolled proliferation (Valko et al., 2007). 
An excessive production of ROS results in oxidative stress, causing damage to 
lipids, proteins and nucleic acids (Diplock et al., 1998). Due to this (uncontrolled) 
redox imbalance various pathologies can emerge. An excessive ROS production has 
been implicated in the pathogenesis of cancer, cardiovascular disease, chronic 
inflammation, neurological and neurodegenerative disorders, diabetes, 
ischemia/reperfusion, ageing and other age-related diseases (Alfadda and Sallam, 
2012; Haenen et al., 1990; Sundar et al., 2013; Van der Vliet and Bast, 1992).  
 
The body contains potent antioxidant defenses which balance the level of oxidants 
and thus preserve homeostasis and protect against damage. One important pathway 
in  the  protection  against  ROS  is  the  Nuclear  factor  erythroid  2-related  factor  2  
(NRF2) pathway (Lyakhovich et al., 2006). The NRF2 pathway is an antioxidant 
defense system to protect against oxidative damage. In this pathway KEAP1 is the 
inhibitor of the transcription factor NRF2. KEAP1 functions as an in vivo sensor for 
ROS and electrophiles, which causes NRF2 to dissociate from the complex and 
translocate to the nucleus (Itoh et al., 1997; Lo et al., 2006). Consequently NRF2 
activates the transcription of numerous detoxifying and antioxidant genes, mediated 
by antioxidant response elements (ARE). The defense system regulates the level of 
detoxifying enzymes as well as non-enzymatic antioxidants (Figure 1). 
 
Chapter 1 
10 
 
Figure 1. Overview of the induction of the adaptive response of the cell by ROS. ROS attack 
KEAP1 and activate the NRF2 pathway which stimulates the transcription of numerous 
detoxifying and antioxidant genes, mediated by antioxidant response elements (ARE) 
Important detoxifying enzymes are superoxide dismutases (SOD), catalases, 
glutathione peroxidases (Gpx) and heme oxygenase 1 (HO-1) (Diplock et al., 1998; 
Surh  et  al.,  2009).  SOD  catalyze  the  conversion  of  superoxide  into  oxygen  and  
hydrogen peroxide. Three forms of SOD exist. SOD1 and SOD3 contain copper and 
zinc, while SOD2 contains manganese. SOD1 is located in the cytoplasm, SOD2 in 
the mitochondria and SOD3 is extracellular (Zelko et al., 2002). 
Catalases catalyze the conversion of hydrogen peroxide to water and oxygen. The 
enzymes are localized in peroxisomes of the cell (Chaudiere and Ferrari-Iliou, 1999; 
Zamocky and Koller, 1999).  
Gpx catalyze the reduction of lipid hydroperoxides to alcohol and hydrogen 
peroxide into water. Different forms exist; Gpx1-Gpx8 which have different 
substrate specificity. Gpx contain selenium and use glutathione (GSH) as cofactor 
(Chaudiere and Ferrari-Iliou, 1999; Flohe, 1978; Yamamoto and Takahashi, 1993).  
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HO-1 catalyzes the degradation of the potentially toxic heme to biliverdin, iron and 
carbon monoxide (Gozzelino et al., 2010). 
The most important non-enzymatic antioxidants are GSH, ascorbate and uric acid. 
GSH is a cysteine-containing tripeptide which is synthesized in cells and therefore 
not required in the diet although cysteine is an essential amino acid (Meister, 1991). 
The antioxidant properties of GSH come from the thiol-group in its cysteine moiety, 
which has reducing as well as nucleophilic properties (Zhang and Forman, 2012). 
Ascorbate is an essential cellular constituent. It must be obtained from the diet 
because it cannot be synthesized by humans (Englard and Seifter, 1986; Pauling, 
1970). Ascorbate is an electron donor and once oxidized, converted into 
dehydroascorbate. Ascorbate can be regenerated from dehydroascorbate by the 
enzyme dehydroascorbate reductase (Chaudiere and Ferrari-Iliou, 1999; Meister, 
1992). 
Uric acid is a product of the metabolic breakdown of purine nucleotides. Uric acid is 
oxidized to alantoine when it scavenges radicals (Becker, 1993; Glantzounis et al., 
2005). 
 
Flavonoids 
Flavonoids are polyphenolic compounds ubiquitously present in fruits, vegetables 
and plant-derived foodstuffs. More than 5000 naturally occurring flavonoids have 
been identified (Nichenametla et al., 2006; Ren et al., 2003). The major dietary 
intake of flavonoids in Western Europe on average is 100-1000 mg per day (Hertog 
et al., 1993; Kozlowska and Szostak-Wegierek, 2014). 
Flavonoids are divided in classes according to their chemical structure. Flavonoids 
have a common basic structure; a carbon skeleton, which consists of two phenyl 
rings (A and B) and mostly a heterocyclic ring (C) (Figure 2). The major classes are 
flavonols, flavones, flavanone, flavanols, anthocyanidins, dihydroflavonols and 
chalcones (Scalbert and Williamson, 2000).  
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Figure 2. Basic structure of flavonoids 
 
Several epidemiological studies showed that a relatively high intake of flavonoids is 
associated with a reduced risk of various chronic diseases, including cardiovascular 
diseases e.g. coronary heart diseases, lung diseases such as COPD and asthma, liver 
disorders (e.g. NAFLD) and certain types of cancers (Queen and Tollefsbol, 2010; 
Tabak et al., 2001; van de Wier et al., 2014; Visioli and Davalos, 2011). In various 
tumor cell lines flavonoids showed anti-proliferative and cytotoxic effects (Choi et 
al., 2001; Naasani et al., 2003; Wang et al., 1999). However, some studies failed to 
show this or even reported an adverse association (Hirvonen et al.,  2001; Knekt et 
al., 2000; Knekt et al., 2002; Rimm et al., 1996). Further research is needed to 
substantiate the protective role of flavonoids in the etiology of chronic diseases. 
The protective effect of flavonoids is due to their effect on a molecular level. 
Flavonoids display a multitude of effects including, antioxidant, antibacterial, 
antiviral, anti-inflammatory, vasodilatory activity (Boots et al., 2008; Cushnie and 
Lamb, 2005; Hu et al., 1994; Middleton et al., 2000; Nichenametla et al., 2006; Park 
et al., 2007; van Acker et al., 2000; Xie et al., 2014). Although it has been studied 
for several decades, the molecular mechanism of flavonoids involved in the 
protection against various pathologies is still enigmatic. 
 
Besides naturally occurring flavonoids semisynthetic flavonoids were developed to 
improve their antioxidant activity, metabolic stability or water solubility. An 
example of such a flavonoid is 7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER), a 
compound derived from the naturally occurring flavonoid rutin. MonoHER is a 
constituent of Venoruton®, a registered drug that is used in the treatment for chronic 
venous insufficiency. The drug contains several hydroxyethylrutosides of which 
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monoHER appeared to be the most powerful antioxidant (van Acker et al., 1993). 
The antioxidant activity was also reflected in its effective protection against 
doxorubicin-induced cardiotoxicity in mice (van Acker et al., 1995). 
 
Molecular mechanism 
Initially, the beneficial effect of antioxidants was ascribed to their direct antioxidant 
effect i.e. their ability to scavenge radicals (Halliwell, 1996). During the scavenging, 
antioxidants donate an electron or a hydrogen atom to the radical involved. In this 
way the radical is neutralized and the noxious potential of the radical is eliminated. 
However, in their protective effect, antioxidants are converted into oxidation 
products that take over part of the reactivity of the radical that is scavenged (Bast 
and Haenen, 2002). Due to this lower reactivity the oxidized antioxidant is less 
noxious, and thus more selective compared to that of the radical. Hence, the 
reactivity of oxidized antioxidants is more selective than that of the initial reactive 
radical (Boots et al., 2002).  
When antioxidant flavonoids exert their scavenging activity, oxidation products - 
called quinones - are formed. To protect against the reactivity of the quinones, cells 
have an antioxidant network. Two well-known antioxidants in this network are 
ascorbate and GSH (Meister, 1994). It should be noted that they neutralize the 
reactivity of the quinones in a different way. Ascorbate reduces the quinones back to 
their parent flavonoid. In contrast, GSH forms GSH-flavonoid adducts (Boots et al., 
2003). The GSH-flavonoid adduct is also reactive towards thiol containing proteins. 
Moreover, GSH is consumed. The way in which quinones channel their reactivity 
into the antioxidant network differs between flavonoids (Boots et al., 2003; Moalin 
et al., 2012). 
 
Aim and outline of the thesis 
In this thesis we further elaborate on the molecular mechanism of the antioxidant 
effect of flavonoids. As described in chapter 1, the molecular mechanism behind the 
protective effect of flavonoids is not clear yet.  
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The contribution of the radical scavenging activity to the antioxidant effect is 
questioned. Therefore, in chapter 2 the direct antioxidant activity of the flavonoid 
monoHER in the protection against intracellular oxidative stress was evaluated at 
several levels, its site specific scavenging effect, its position in the antioxidant 
network and its location in the vascular system. 
After scavenging, flavonoids are oxidized and become reactive themselves. In 
chapter 3 the channeling of the reactivity of the structurally related oxidized 
flavonoids, quercetin and tamarixetin, towards the thiol containing proteins, CK or 
into the antioxidant network, specifically towards ascorbate, is determined. 
When flavonoids scavenge ROS, the oxidative damage is prevented. The protection 
against ROS can backfire because the activation of the innate NRF2 pathway might 
be prevented as well. As a consequence, no protective adaptation is elicited because 
antioxidant administration prevents the endogenous defensive shield to be raised. 
The effect of monoHER on the cellular adaptive response is studied in chapter 4. 
In chapter 5 the effect of monoHER on oxidative stress and the adaptive response 
during the onset of NAFLD was determined in an animal model. The effect was 
evaluated on three levels, namely the direct damage by ROS, the NRF2-induced 
gene expression and the adaptive response on the cellular redox status.   
In mice, monoHER protects against doxorubicin-induced cardiotoxicity. The 
contribution of the major metabolite, 4’-O-methylmonoHER to the antioxidant 
activity of monoHER was investigated in chapter 6. The metabolite was 
synthesized and its antioxidant activity was evaluated and compared to that of 
monoHER. Besides the potency to scavenge radicals, the channeling of the reactivity 
of the oxidized product towards proteins was studied. 
Chapter 7 puts  the  findings  of  the  present  study  in  a  further  perspective.  The  
antioxidant, anti-inflammatory and other activities and their contribution to the 
beneficial health effects of the nutraceutical monoHER is discussed.  
Finally, the most important results and future perspectives are discussed in    
chapter 8. 
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Abstract 
 
The flavonoid 7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) is an effective 
protector against doxorubicin induced toxicity which has been related to the 
antioxidant activity of monoHER. The present study examines the potential 
relevance of the direct scavenging activity of the flavonoid. 
The potency of the direct antioxidant effect was confirmed by its instantaneous 
protection against intracellular oxidative stress in human umbilical vein endothelial 
cells at therapeutically achievable concentrations (EC50 = 60 nM) underpinning the 
involvement of a direct scavenging activity. This direct effect of monoHER is 
substantiated by (i) its site specific scavenging effect, i.e. on a molecular level 
monoHER is positioned at the location of radical formation, (ii) its position in the 
antioxidant network, i.e. on a biochemical level oxidized monoHER quickly reacts 
with ascorbate or glutathione, (iii) its location in the vascular system, i.e. on a 
cellular level monoHER is localized in the endothelial and smooth muscle cells in 
the vascular wall. 
It is concluded that the flavonoid monoHER can display a physiologically important 
direct antioxidant effect. 
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Introduction 
 
7-Mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) belongs to the group of the 
flavonoids. Flavonoids are a group of naturally occurring polyphenolic compounds 
that are present in vegetables, fruits and plant-derived beverages such as tea and 
wine (Nichenametla et al., 2006; Ren et al., 2003). The most studied biochemical 
activity of this group of compounds is their ability to protect against oxidative stress. 
A high flavonoid intake correlates with a reduced risk of developing e.g. 
cardiovascular diseases, which has been linked to the antioxidant activity of the 
flavonoids (Diplock et al., 1998; Middleton et al., 1994). New flavonoids have been 
designed to optimize the health effects. MonoHER is a semi-synthetic flavonoid and 
is the most active component of the registered drug Venoruton®. Venoruton® 
protects the vascular endothelium and mitigates inflammation (Bast et al., 2007). 
MonoHER is also a potent protector against doxorubicin-induced cardiotoxicity. 
This has also been associated with its excellent antioxidant properties (Haenen et al., 
1993; van Acker et al., 1993). 
The relevance of a direct antioxidant effect is debated (Gordon, 2012; Hollman et 
al., 2011; Hu, 2011; Stevenson and Hurst, 2007). In the present study, the direct 
antioxidant activity of the flavonoid monoHER in the protection against intracellular 
oxidative stress was evaluated at several levels. To this end a relatively stable 
reactive oxygen species (ROS), namely H2O2, was used to induce a reproducible 
oxidative stress. H2O2 is formed in cells in various ways, e.g. in the oxidative 
phosphorylation that leads to the formation of superoxide radicals that dismutate to 
H2O2. H2O2 readily enters the cell through aquaporin channels (Miller et al., 2010). 
Intracellular, the relatively unreactive H2O2 can be converted into the extremely 
reactive OH-radical, that induces radical damage itself and also amplifies ROS 
production through e.g. enhanced intracellular iron uptake, and activation of radical 
production by mitochondria, NAD(P)H oxidase, xanthine oxidase and uncoupled 
eNOS (Cai, 2005; Li et al., 2010).  
The direct antioxidant activity of monoHER was quantified in a radical scavenging 
assay, and further evaluated on a cellular level. Since Venoruton®, with monoHER 
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as principle component, efficiently protects the vascular endothelium, endothelial 
cells (i.e. HUVEC’s) were selected for the cellular experiments.  
It was concluded that due to its high antioxidant potential, its interplay with other 
antioxidants in the antioxidant network and its presence at the site of action, the 
flavonoid is able to directly protect against oxidative stress.  
 Direct antioxidant effect 
23 
Materials and methods 
 
Chemicals 
7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) was kindly provided by Novartis 
Consumer Health (Nyon, Switzerland). 2-Deoxy-D-ribose, ferric chloride 
hexahydrate (FeCl3.6H2O), ascorbic acid were purchased from Sigma (St. Louis, 
USA). H2O2 was obtained from Riedel-de Haën (Seelze, Germany). 2-thiobarbituric 
acid (TBA) and EDTA were purchased from Merck (Darmstadt, Germany). 2',7'-
dichlorofluorescein-diacetate (DCFH-DA), horseradish peroxidase (HRP), reduced 
nicotinamide adenine dinucleotide (NADH), 2,4-dinitrophenylhydrazine (DNPH) 
and reduced glutathione (GSH) were acquired from Sigma (St. Louis, USA).  
Trichloroacetic acid (TCA) was obtained from Serva (Heidelberg, Germany). 
Ethanol was purchased from VWR prolabo (Fonteney sous Bois, France). Human 
Umbilical Vein Endothelial Cells (HUVECs) cell line-1730 was obtained from 
ATCC (Manassas, USA). Hank’s balanced salt solution (HBSS) was obtained from 
Invitrogen (Breda, The Netherlands).  
 
Cell culture 
HUVECs were cultured in T75 coated culture flasks (Greiner Bio-one, Alphen a/d 
Rijn, The Netherlands) in Ham’s F12-K medium (Invitrogen, Breda, The 
Netherlands) supplemented with 10 % (v/v) fetal calf serum (FCS; Invitrogen, 
Breda, The Netherlands), 0.05 mg/ml endothelial cell growth supplement (ECGS; 
BD  Science,  Franklin  Lakes,  USA),  1  %  pen/strep  (Gibco,  Bleiswijk,  The  
Netherlands) and 0.01 mg/ml heparin (LEO Pharma, Ballerup, Denmark) in a 
humidified atmosphere containing 5 % CO2 and  95  %  air  at  37  °C.  The  maximal  
passage used was 20 in the measurement of intracellular oxidative stress. 
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Measurement of intracellular oxidative stress 
The intracellular levels of oxidative stress were quantified by the fluorescence of 
DCF. The probe used has broad specificity; it detects H2O2, hydroxyl radicals, 
superoxide and other reactive species. 
Cells (4 X 104 per well) were plated out in a 96-wells plate (Greiner Bio-one, 
Alphen a/d Rijn, The Netherlands) 24 h before the experiment. The cells were then 
incubated with 20 µM DCFH-DA in 5 % CO2 and 95 % air at 37 °C for 45 min. 
After the medium with excess of DCFH-DA was removed, the cells were rinsed 
once with HBSS and subsequently incubated with 200 µM H2O2 and  0-1  µM  
monoHER or 1 mM ethanol in serum-free medium. The fluorescence (Ex 485 nm, 
Em 538 nm) was determined on a microplate reader (Spectramax microplate reader, 
Molecular devices, Sunnyvale, USA) as a measure of oxidative damage. 
The EC50, the concentration of monoHER which reduces intracellular oxidative 
stress by 50 % after 45 min, was determined by plotting the logarithm of the 
concentration of monoHER against the protection (in %) at time point 45 min. The 
EC50 was estimated by linear interpolation between the concentration 0.01 µM and 
0.1 µM. 
Measurement of DCF in the medium revealed that in none of the incubations DCF 
leakage occurred (data now shown). 
The  reaction  of  monoHER  or  ethanol  with  H2O2 was examined by HPLC and 
spectrophotometrically (data not shown). Both compounds did not react with H2O2.   
 
Cell viability  
HUVECs (4 X 104 per well) were plated out in a 96-wells plate (Greiner Bio-one, 
Alphen a/d Rijn, The Netherlands). The next day, medium was removed and cells 
were washed once with HBSS and exposed to serum-free medium containing test 
compounds for 45 min. After exposure, 20 µl of medium was transferred to a new 
96 well plate to measure lactate dehydrogenase (LDH) activity. Fifty µl of 10 mg/ml 
NADH in 0.75 mM sodium pyruvate was added to the medium and incubated for 30 
minutes at 37 ºC. To determine the remaining amount of pyruvate, 50 µl 0.2 mg/ml 
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DNPH was added to the wells and incubated at room temperature in the dark for 20 
minutes. After incubation with DNPH, 50 µl 4 M NaOH was added and the mixture 
was incubated for 5 minutes to develop the color. Absorbance was measured at 540 
nm using a Spectramax plate reader (Molecular Devices, Sunnyvale, CA, USA) and 
viability was calculated relative to unexposed cells (100 % viability) with 0.1 % 
(v/v) triton X-100 as a positive control. 
 
Hydroxyl radical scavenging competition assay 
In the assay, the scavenger, monoHER or ethanol, is in competition with 
deoxyribose for a reaction with hydroxyl radicals. The hydroxyl radicals are formed 
in the reaction between Fe2+ and H2O2. Iron is kept in the reduced form by ascorbate 
acid. 
The reaction mixtures contained, unless stated otherwise, 0-0.4 mM monoHER or 0-
0.4 mM ethanol, 2.8 mM deoxyribose, 100 µM ascorbic acid and 2.8 mM H2O2 in 
20 mM KH2PO4/K2HPO4 buffer pH 7.4. Hydroxyl radical formation was started by 
adding 200 µl of a solution containing 20 µM FeCl3 and 0-100 µM EDTA in 
deoxygenated water. The mixture was incubated at 37 °C, and after 1 h 2 ml of a 
solution, containing 0.5 % TBA and 1.4 % TCA was added. Subsequently, the 
mixture  was  heated  at  100  °C  for  20  min.  The  test  tubes  were  cooled  to  room  
temperature. The absorbance (A) of the reaction mixture was measured at 532 nm. 
By plotting the reciprocal of the relative absorbance against the concentration of the 
scavenger, the apparent reaction rate constant (ks)  of  the  reaction  between  the  
scavenger and the hydroxyl radicals was calculated according to (Halliwell et al., 
1987). 
 
Reaction of oxidized monoHER with GSH and/or ascorbate 
MonoHER (50 µM) was oxidized by 1.6 nM HRP and 33 µM H2O2 in a 145 mM 
phosphate buffer pH 7.4, at 37 °C. The concentration of ascorbate and GSH was 40 
µM when present. The reaction was monitored spectrophotometrically (monoHER 
consumption at 355 nm, ascorbate consumption at 270 nm) and by high-
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performance liquid chromatography (HPLC) as previously described by Jacobs et 
al., 2010 (Jacobs et al., 2010). The absorption spectra were recorded on a Varian 
Carry 50 spectrophotometer (Mulgrave, Australia) from 220 to 500 nm with a scan 
speed of 960 nm/min, using quartz cuvettes. HPLC analysis was performed on a HP 
1100 series HPLC system (Agilent Technologies, Palo Alto, USA) using a 
Supelcosil LC 318 column (5 µm, 25 cm x 4.6 mm) (Supelco, Bellefonte, USA). 
The mobile phase consisted of water with linear gradients of acetonitrile, containing 
0.1 % (v/v) TFA. MonoHER was detected with a diode array detector at 355 nm 
(absorption maximum of monoHER). 
 
Localization of monoHER in carotid arteries by two photon laser scanning 
microscopy 
The animal protocol was approved by the Ethics committee for Animal Experiments 
of Maastricht University (Maastricht, The Netherlands). C57BL/6J mice were used 
to isolate the carotid artery. The arteries were incubated with HBSS and afterwards 
with 200 µM monoHER for 30 min at 37 °C. The arteries were rinsed with HBSS to 
remove the unbound monoHER.  
 
The carotid arteries were imaged using TPLSM (TCS SP5 CFS AOBS with a 
Coherent: Chameleon Ultra II.  ir. 140 fs pulsed laser system >300 KW, for 2 photon 
excitation at 800 nm, Emission filter: 510 - 580 nm) (Leica Microsystems, Wetzlar, 
Germany). A HCX APO L 20.0 x 1.00 water objective (WD = 2.0 mm) was used. A 
nucleus specific staining with SYTO 41 was carried out. Images were obtained using 
LAS-AF SP5 software. No further image processing was carried out. 
 
Statistics 
Three independent experiments were performed. Data are expressed as mean ± SD 
or a typical example is shown. Statistical analysis was performed using Student’s t-
test. P values  0.05 were considered statistically significant. 
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Results  
 
Protection against intracellular oxidative stress 
H2O2 added to HUVECs in a concentration of 200 µM, induced intracellular 
oxidative stress (Figure 1). Immediately after addition, monoHER protected 
HUVECs against the intracellular oxidative stress. The EC50 after  45  min  was  60  
nM. Ethanol in a concentration up to 1 mM did not protect against intracellular 
oxidative stress. In none of the incubations, significant LDH leakage was observed 
(data not shown). 
 
 
Figure 1. The effect of ethanol and monoHER on the intracellular oxidative stress induced by 
200 µM H2O2 in human umbilical vein endothelial cells, except for the basal level, which was 
without H2O2. Intracellular oxidative stress is measured using DCF fluorescence as described 
in the materials and methods section. A typical example is shown. In the insert (B) the 
oxidative stress after 45 min is shown. Three independent experiments were performed in 
quadruplicate and data are shown as mean ± SD (significantly lower than 0 µM monoHER 
*P<0.05,**P<0.001). 
 
Hydroxyl radical scavenging/direct antioxidant activity 
The competition experiment with deoxyribose showed that monoHER is a very 
potent antioxidant (Figure 2). The apparent second order reaction rate constant (ks) 
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of the reaction of monoHER with the hydroxyl radicals, was 130 X 108 M-1s-1. The 
reference compound ethanol proved to be less potent than monoHER (Figure 2). The 
ks of ethanol obtained was 25 X 108 M-1s-1, which is similar to previously reported 
values (Halliwell et al., 1987). 
 
 
Figure 2. Determination of the hydroxyl radical scavenging activity of monoHER and ethanol 
using a competition assay with deoxyribose. The deoxyribose concentration is 2.8 mM. The 
concentration of the scavenger is plotted on the x-axis. To determine the scavenging activity 
of monoHER and ethanol, the breakdown products formed in the reaction of deoxyribose with 
OH-radicals were measured spectrophotometrically. MonoHER and ethanol compete with 
deoxyribose for the OH-radicals and the presence of these compounds reduces the 
concentration of deoxyribose breakdown product. The absorbance obtained in the presence of 
monoHER or ethanol (A) was related to the absorbance obtained without these compounds 
(A0) which is a measure of the scavenging activity. Three independent experiments were 
performed and data are shown as mean ± SD. The apparent reaction rate (ks) of the reaction of 
monoHER and ethanol with hydroxyl radicals with or without ETDA is shown in the insert 
(B). Data are shown as mean ± SD (n=3). *Significant difference between ks with EDTA and 
ks without EDTA P<0.001. 
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Omitting the chelator EDTA from the reaction mixture, increased the observed 
potency of monoHER (Figure 2); the apparent ks of monoHER was 980 X 108 M-1s-1. 
The results (Figure 2) also show that the apparent ks of  ethanol  in  the  absence  of  
EDTA (4  X 108 M-1s-1)  was  245 times  lower  than  that  of  monoHER and six  times  
lower than that of ethanol in presence of EDTA.  
 
Reactivity of oxidized monoHER with the endogenous antioxidants GSH or 
ascorbate 
MonoHER oxidized in the presence of GSH generates a GSH-monoHER adduct. In 
the presence of ascorbate, no net consumption of monoHER is observed, while 
ascorbate is consumed (Figure 3). The fast ascorbate consumption is due to the 
instantaneous reduction of oxidized monoHER to monoHER. A competition 
experiment demonstrated that oxidized monoHER reacted 2.5 times as fast with 
ascorbate (3.0 ± 0.3 µM/min) as with GSH (1.3 ± 0.1 µM/min).  
 
 
Figure 3. Location of monoHER in the antioxidant network. In the presence of 40 µM GSH 
(A), the combination of 40 µM GSH and 40 µM ascorbate (B) or 40 µM ascorbate (C), 50 µM 
monoHER was oxidized. The relative importance of the reactions is depicted by the width of 
the arrow and given by the percentage. 
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Localization of monoHER in the carotid artery 
Incubation of the carotid arteries with monoHER and subsequent TPLSM analysis 
showed that monoHER was retained in the wall of the artery (Figure 4A and 4B). 
The arteries were also stained with SYTO 41 (Figure 4C). The fluorescence of this 
nucleus specific stain overlaps with the fluorescence of monoHER (Figure 4D).  
 
  
Figure 4. Localization of monoHER in the carotid artery. Two Photon Laser Scanning 
Microscopy imaging of longitudinal cross-sections of an intact carotid artery incubated with 
HBSS (A), 200 µM monoHER (B), a nuclei staining dye, SYTO 41 (C) and both monoHER 
and SYTO 41 (D). A typical example is shown. The elastic lamina autofluoresce in the same 
wavelength range as monoHER, i.e. emission 510-580 nm, and are therefore visible. The 
fluorescence obtained after addition of SYTO 41, overlaps with the fluorescence of 
monoHER. This indicates that monoHER is located in the nuclei of the endothelial cells 
(round spots) and smooth muscle cells (elongated spots). 
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Discussion 
 
MonoHER is a semi-synthetic flavonoid which was found to display a very potent 
antioxidant activity (Haenen et al., 1993; van Acker et al., 1993). This flavonoid 
proves to have several beneficial effects on the cardiovascular system. As the main 
constituent of the registered drug Venoruton®, monoHER improves the function of 
the endothelial layer of the vessels in the treatment of chronic venous insufficiency 
(Cesarone et al., 2006). MonoHER was also found to effectively protect against 
doxorubicin-induced cardiotoxicity in mice (van Acker et al., 2000; van Acker et al., 
1995).  
In the present study the potential contribution of the direct antioxidant effect of 
monoHER against oxidative stress was elucidated by evaluating the effect at 
different levels i.e. the molecular, supramolecular, and cellular level. 
 
Protection against intracellular oxidative stress 
Initially, the beneficial effect of antioxidants was ascribed to their direct antioxidant 
effect i.e. their ability to scavenge radicals (Halliwell, 1996). This could directly 
neutralize the noxious potential of radicals. The plausibility of a physiological 
relevant effect of radical scavenging of antioxidants is seriously questioned because 
of the high concentration of antioxidant that is needed for this type of protection, a 
concentration that is impossible to be reached in vivo (Gordon, 2012; Hollman et al., 
2011; Hu, 2011; Stevenson and Hurst, 2007).  
In line with this hypothesis, we found that the well known OH-radical scavenger 
ethanol was not able to protect against intracellular oxidative stress in HUVECs, 
even at relatively high concentrations. Apparently, radical scavenging on its own is 
not sufficient to offer effective protection. 
In the case of monoHER, we found that the flavonoid does protect cells against 
oxidative stress, even at a low concentration (the EC50 was 60 nM). The probe used 
to detect oxidative stress reacts with a broad array of reactive species, suggesting a 
full protection by monoHER. A study in human volunteers demonstrated that 
monoHER can reach plasma concentrations up to 360 µM after i.v. administration 
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(Willems et al., 2006). This points out that monoHER can provide an effective 
protection at therapeutically achievable concentrations.  
The in vivo effectiveness was demonstrated by the protection of monoHER against 
doxorubicin- induced cardiotoxicity in mice. MonoHER administered 30 min before 
doxorubicin could prevent oxidative damage to the heart (Bruynzeel et al., 2006). In 
this effect the antioxidant activity of metabolites of monoHER has to be taken into 
account (Jacobs et al., 2011a; Jacobs et al., 2011b). We have also identified that 
monoHER immediately offered protection in HUVECs. The fact that the protection 
by monoHER is instantaneous, precludes the involvement of e.g. the induction of 
antioxidant enzymes because such an indirect mechanism requires several hours to 
be effective due to the time needed for transcription factor activation, DNA 
transcription, mRNA production, protein synthesis and protein processing. That the 
effective protection was observed immediately after the addition of monoHER, 
confirms that a direct antioxidant activity of monoHER is involved in the protection 
of the HUVECs. 
 
Scavenging activity 
To induce oxidative stress in the cells, HUVECs were exposed to H2O2.  H2O2 is 
relatively unreactive and can readily diffuse over membranes. By the use of H2O2, 
that in the concentration used did not induce LDH leakage, we were able to impose a 
reproducible and relatively mild oxidative stress upon the cells. H2O2 can produce 
intracellular oxidative stress by reacting with iron to generate the extremely reactive 
OH-radicals in a Fenton reaction (Wardman and Candeias, 1996). The extreme 
reactivity of radicals fueled the debate on the relevance of radical scavenging 
antioxidants, because it would be impossible for antioxidants to neutralize the 
radical before it attacks vital cellular compounds (Bast and Haenen, 2013). 
Remarkably,  in  the  present  study we found that  monoHER did  protect  against  the  
intracellular stress directly after addition. This also indicates that metabolites are not 
likely to be involved, and that this instantaneous effect is primarilly attributable to 
monoHER itself.  
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In addition, our results of the hydroxyl radical scavenging competition assay show 
that monoHER scavenges OH-radicals at an extremely high apparent rate in our test 
system - ks = 980 X 108 M-1s-1 - which is even quicker than the diffusion rate (~ 100 
X 108 M-1s-1).  This can be explained by site-specific scavenging. Essential for this 
activity is that monoHER can chelate iron (van Acker et al., 1998). The result of this 
chelation is that monoHER is present at the site of the radical formation, i.e. the iron 
ion. This enables monoHER to immediately scavenge the newly formed radical. By 
this site-specific scavenging, monoHER is able to prevent damage to critical 
biomolecules such as lipids, proteins or DNA, despite the high reactivity of the 
radical. 
 
Reactivity in the antioxidant network 
Due to the site-specific scavenging, monoHER is the first molecule to react with the 
generated radicals. In the scavenging reaction monoHER donates an electron or a 
hydrogen atom to the radical involved. The radical is converted into a relatively 
stable non-radical, e.g. the hydroxyl radical becomes H2O. MonoHER is oxidized 
and takes over part of the reactivity of the radical (Bast and Haenen, 2002). 
Fortunately, the body is endowed with an intricate network of antioxidants in which 
monoHER can pass over its reactivity (Bast et al., 1991; Jacobs et al., 2010; Meister, 
1994). The main antioxidants in this network are GSH and ascorbate. When 
oxidized monoHER reacts with GSH, a GSH-monoHER adduct is formed (Jacobs et 
al., 2009). Although oxidized monoHER can react with GSH, it is preferentially 
recycled in a redox reaction with ascorbate. The oxidized ascorbate formed in this 
redox reaction can, on its turn, be reduced, e.g. by dehydroascorbate reductase that 
uses  NADH  as  a  cofactor.  In  this  way,  the  reactivity  of  the  radical  is  completely  
neutralized and the antioxidant network fully restored.  
The actual mechanism of action is that the antioxidant monoHER functions as a 
catalyst that  (i) efficiently scavenges the radical involved, (ii) subsequently safely 
channels the reactivity of the radical into the endogenous antioxidant network and 
(iii) finally is recycled and thus helps to maintain homeostasis. 
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Localization in the cardiovascular system 
Neumann et al. monitored the uptake of O-(ȕ-hydroxyethyl)-rutosides, among which 
monoHER at a subcellular level, in varicose long saphenous veins, after i.v. 
administration (Neumann et al., 1992). They found that these flavonoids were 
localized in the endothelial and sub-endothelial layer of the vessel. Our results are in 
line with this observation. Our experiments with carotid arteries showed that 
monoHER is retained in the wall of these arteries with TPLSM analysis.  
The fluorescence was localized in the nucleus of the cell. This finding was in line 
with the observation of Mukai et al. (Mukai et al., 2009). They found that flavonols 
added to cultured Hepa-1c1c7 cells also accumulated in the nucleus of these cells. A 
favorable localization in the cardiovascular system supports the protective potential 
of monoHER.  
 
Location, location, location… 
The fundamental prerequisite for a bioactive compound to have a biologic effect is 
that the compound has to closely interact with its biological targets, a concept coined 
by Ehrlich in 1913 as ‘Corpora non agunt nisi fixata’ (Ehrlich, 1913). At first sight, 
radical scavengers do not seem to meet this criterion, which fuels the debate on their 
biological activity. However, the present study shows that the concept of Ehrlich 
does apply for monoHER. The interactions needed for a biological effect are 
favorable on (i) the molecular level; monoHER is at the right location for radical 
scavenging, (ii) the supramolecular level; monoHER is located at a pivotal position 
in the antioxidant network and (iii) the cellular level; monoHER is located in the 
endothelial and smooth muscle cells in the vascular wall.  
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Abstract 
 
Antioxidants act as intermediates by picking up the high unselective reactivity of 
radicals and transferring it to other molecules. In this process the reactivity is 
reduced and becomes selective. This channeling of the reactivity can cause selective 
toxicity. The antioxidant quercetin is known to channel the reactivity towards thiol 
groups. The present study compares the thiol reactivity of quercetin with that of 4’-
O-methylquercetin (tamarixetin) towards creatine kinase (CK), a vital protein that 
contains a critical thiol moiety. Our results showed that oxidized quercetin and 
oxidized tamarixetin both adduct CK, which then loses its enzymatic function. 
Ascorbate, an important representative of the antioxidant network, is able to prevent 
adduction to and thus the inhibition of the enzyme by tamarixetin but not by 
quercetin. Apparently, tamarixetin is less thiol toxic than quercetin, because - rather 
than adduction to CK - tamarixetin quinone prefers to pass reactivity to the 
antioxidant network, i.e., to ascorbate. The findings exemplify that radical 
scavenging flavonoids pick up the reactivity of radicals and act as a pivot in 
directing the way the reactivity is channeled. A mere minor structural difference of 
only one methyl moiety between quercetin and tamarixetin appears to have a high 
impact on the selective, thiol toxicity.  
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Introduction 
 
Flavonoids are polyphenols found in numerous fruits and vegetables having 
excellent antioxidant properties. After their discovery, the prevailing idea was that 
antioxidant intake was exclusively linked to health benefits. Antioxidants were 
thought to protect against radicals by simply scavenging them and thus fully 
annihilating their reactivity (Halliwell, 1996; Willcox et al., 2004). Contemporary 
research acknowledges this protective effect and append that by scavenging also 
reactive intermediates of the antioxidant are formed, which can be toxic (Bjelakovic 
et al., 2014).  
Flavonoids are extraordinary potent antioxidants; this places them at the top of the 
pecking order meaning that flavonoids are first in line to scavenge reactive oxygen 
species (ROS). ROS take up an electron or hydrogen atom from the antioxidant 
flavonoid and this reduction converts the ROS into relatively harmless species. The 
oxidized flavonoids formed in the scavenging reaction are less reactive than the 
radical scavenged, which leads to selective reactivity. Oxidized flavonoids readily 
and specifically adduct thiol groups. Hence, oxidized flavonoids may threat vital 
cellular compounds containing a critical thiol group (Boots et al., 2002; Ito et al., 
1988). Apparently, a paradox is hidden in the functioning of an antioxidant 
flavonoid. Flavonoids protect against the reactivity of ROS but the other side of the 
coin is that during their protective effect, a potential thiol toxic product is formed. 
The thiol containing enzyme creatine kinase (CK) is crucial for energy production in 
cells with a high energy turnover. Oxidative stress forms an onslaught on the energy 
level of the cell. Inhibition of CK aggravates the energy crisis which can finally lead 
to cell death (Reddy et al., 2000). This prompted us to examine thiol toxicity on CK. 
The selective toxicity toward protein thiols might be circumvented when the 
reactivity of the oxidized flavonoid is absorbed by the antioxidant network of the 
cell. Ascorbate, an important representative in this network, can efficiently reduce 
an oxidized flavonoid and thus recycle the flavonoid. In this way the radical is 
neutralized by channeling its reactivity safely into the antioxidant network. 
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The flavonoids of interest to us are quercetin and the 4’-O-methylquercetin, 
tamarixetin. Quercetin and tamarixetin are naturally occurring flavonoids which are 
present in our diet. Tamarixetin is also a metabolite of quercetin that is formed in 
vivo (Brevik et al., 2004). The cellular uptake of tamarixetin is higher than that of 
quercetin (Spencer et al., 2003). This supports a potential role of tamarixetin in vivo. 
In this study the canalization of the reactivity of structurally related flavonoids, 
quercetin and tamarixetin, is unraveled at the level of protein reactivity because 
toxicity arises at this level. The preference of the oxidized flavonoids to direct their 
reactivity towards thiol containing proteins like CK or into the antioxidant network, 
specifically towards ascorbate, is determined. It is found that the minor difference in 
structure, i.e., the 4’-O-methyl group, has a profound effect. 
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Materials and Methods 
 
Chemicals 
Quercetin was purchased from Acros Organics (Geel, Belgium). Tamarixetin was 
obtained from Extrasynthese (Genay, France). Hydrogen peroxide (H2O2), L-
ascorbic acid, horseradish peroxidase (HRP) and creatine kinase (CK) were obtained 
from Sigma (St. Louis, MO, USA). The creatine kinase kit was acquired from Bioo 
Scientific Corporation (Austin, TX, USA). Trypsin was purchased from Promega 
(Madison, WI, USA). Ammonium bicarbonate (ABC), acetonitrile (ACN), Į-cyano-
4-hydroxycinnamic acid and trifluoroacetic acid (TFA) were acquired from Sigma 
(St. Louis, MO, USA). 
 
Creatine Kinase activity 
Quercetin and tamarixetin quinones were generated in situ by oxidizing the 
flavonoids (50 µM) with 50 µM H2O2 and 0.4 nM HRP in case of quercetin and 3.2 
nM HRP in case of tamarixetin to obtain an equal rate of oxidation of the flavonoid 
(5 µM/min), in the presence of 6.2 µM CK in a 145 mM potassium-phosphate buffer 
pH 7.4. The influence of ascorbate was determined by adding 50 µM to the reaction 
mixture. The reactions were started by adding the HRP and carried out at 37 °C for 5 
min.  
Enzyme activity of creatine kinase (CK) in the reaction mixtures was measured by 
the catalytic conversion of ADP into ATP. Because ascorbate prevented the net 
consumption of tamarixetin, it was checked whether ascorbate did prevent the 
oxidation of tamarixetin. It was found that ascorbate did not inhibit the oxidation, 
but immediately reduced the oxidized tamarixetin (supplemental data). Hexokinase 
was used to convert ATP with glucose into glucose-6-phosphate. Finally, the 
glucose-6-phosphate formed converts NAD+ into NADH in the presence of glucose-
6-phosphate dehydrogenase. The formation of NADH was measured 
spectrophotometrically at 340 nm during 5 min and reflects the CK activity.  
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Mass spectrometry 
In the presence of 6.2 µM CK in 50 mM ABC buffer pH 7.4, quercetin and 
tamarixetin (50 µM) were oxidized by 50 µM H2O2 and 0.4 or 3.2 nM HRP, 
respectively. The influence of ascorbate was determined by adding 50 µM to the 
reaction mixture. The oxidation reaction was carried out at 37 °C for 5 min. CK (0.5 
mg/mL) was digested by adding 1 µg trypsin during 30 minutes at 37°C. The 
digested samples were diluted 1:10 in 0.1% TFA. After dilution, 1 µL of the digest 
and 1 µL of matrix solution (2.5 mg/mL Į-cyano-4-hydroxycinnamic acid in 50% 
ACN/0.1% TFA) were spotted on a 348-well-format target plate and air dried. Mass 
spectra were measured on the MALDI-TOF mass spectrometer (4800 MALDI-TOF 
analyzer; Applied Biosystems, Bridgewater, NJ, USA). The instrument was operated 
in positive reflector mode. Acquisition mass range was 800–3500 Da. 
 
Statistics 
All experiments were performed at least in triplicate. Data are expressed as means ± 
standard error (SE). 
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Results  
 
Quercetin quinone and tamarixetin quinone inhibit creatine kinase  
Quercetin quinone and tamarixetin quinone were generated in situ in an incubation 
mixture containing CK. Quercetin quinone was found to reduce CK activity (95%). 
Tamarixetin quinone also attenuated the activity of CK, but the extend of this 
reduction was less (20%) than that in the experiment with quercetin despite the equal 
rate of quinone formation (Figure 1). 
 
 
Figure 1. Structure and Lowest Unoccupied Molecular Orbital (LUMO) localization map of 
the preferred tautomer of quercetin quinone and tamarixetin quinone, and the effect of 
quercetin and tamarixetin oxidation on the enzyme activity of creatine kinase (CK). The 
carbonyl groups of quercetin quinone are positioned at maximal distance within the molecule 
and the LUMO is distributed over the phenolic rings, which explains why it behaves as a soft 
electrophile. Tamarixetin quinone has a positive charge and the LUMO is focused in the B-
ring, which makes it a relatively hard electrophile. Quercetin and tamarixetin (50 µM) were 
oxidized by 50 µM H2O2 and 0.4 or 3.2 nM horseradish peroxidase (HRP), respectively, to 
obtain an equal rate of oxidation (5 µM/min). In the presence of 6.2 µM CK, the enzyme 
activity of CK was measured. Data are shown as mean ± SE (n = 4). 
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Ascorbate only slightly protected against the inhibition of the activity caused by 
quercetin quinone (from 95% to 72%). In contrast, ascorbate completely protected 
the enzyme against the inactivation by the tamarixetin quinone, because the activity 
of CK was fully retained (Figure 2).  
 
 
Figure 2. Effect of quercetin and tamarixetin oxidation on the enzyme activity of CK in 
presence of ascorbate. Quercetin and tamarixetin (50 µM) were oxidized by 50 µM H2O2 and 
HRP, at equal rate of oxidation (5 µM/min) in presence of 6.2 µM CK. The enzyme activity of 
CK was measured in the absence or presence of 50 µM ascorbate and expressed as percentage 
of the CK inhibition obtained without ascorbic acid. Data are shown as mean ± SE (n = 4). 
 
Quercetin quinone and tamarixetin quinone adduct creatine kinase  
After reaction of CK with quercetin quinone and tamarixetin quinone and 
subsequent trypsin digestion, MALDI-TOF analysis showed that the amount of the 
native peptide fragment - GYTLPPHCSR with a mass of m/z = 1130 - was reduced. 
Fragments  with  a  mass  of  m/z = 1430 or 1444 emerged after incubation with 
quercetin or tamarixetin, respectively (Figures 3 and 4). The increments of the mass 
of the fragment correspond to the molecular weight of the quinones, being 300 Da 
and 314 Da, respectively. Apparently, the flavonoid quinones adduct creatine kinase. 
The  amount  of  adducted  fragment  formed  was  less  after  the  reaction  with  
tamarixetin quinone than after the reaction with quercetin quinone (Figures 3 and 4). 
Ascorbate effectively prevented the formation of the flavonoid-protein fragment in 
the case of tamarixetin quinone but not in the case of quercetin quinone (Figures 3 
and 4).  
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Figure 3. MALDI-TOF analysis of isolated creatine kinase (CK) (0.5 mg/mL) incubated with 
50 µM quercetin, 0.4 nM HRP and 50 µM H2O2 with or without 50 µM ascorbate for 5 min at 
37 °C. After trypsin digestion the mass spectrum of digested CK was measured. The control 
spectrum of CK displayed a peak at m/z 1130 and no peak at m/z 1430. The incubation with 
quercetin showed a peak at m/z 1430 which corresponds to the mass of the adduct of quercetin 
quinone (300 dalton) with the peptide having mass m/z 1130, whereas the peak at m/z 1130 
decreased. The amino acid sequence of the peptide is GYTLPPHCSR, containing cysteine 
146. The spectrum of CK incubated with quercetin in combination with ascorbate also 
showed a peak at m/z 1430. The peak at m/z 1130 was also present, but the relative intensity 
(RI) was less than the untreated CK.  
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Figure 4. MALDI-TOF analysis of isolated creatine kinase (CK) (0.5 mg/mL) incubated with 
50 µM tamarixetin, 3.2 nM HRP and 50 µM H2O2 with or without 50 µM ascorbate for 5 min 
at  37  °C.  After  trypsin  digestion  the  mass  spectrum  of  digested  CK  was  measured.  The  
control spectrum of CK displayed a peak at m/z 1130 and no peak at m/z 1444. The 
incubation with tamarixetin showed a peak at m/z 1444 which corresponds to the mass of the 
adduct of tamarixetin quinone (314 dalton) with the peptide having mass m/z 1130, whereas 
the peak at m/z 1130 decreased. The amino acid sequence of the peptide is GYTLPPHCSR, 
containing cysteine 146. The spectrum of CK incubated with tamarixetin in combination with 
ascorbate did not show a decrease in the intensity of the peak at m/z 1130 and an increase at 
m/z 1444. 
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Discussion 
 
Amongst antioxidants, flavonoids are at the top of the pecking order meaning that 
these antioxidants are first in line to react with radicals. Therefore, flavonoids can 
effectively protect against radical toxicity (Bast and Haenen, 2013). In this 
protection the flavonoids become oxidized. Due to their quinone structure, oxidized 
flavonoids react with nucleophilic thiol groups predominantly found in GSH and 
cysteine residues of proteins, resulting in selective thiol toxicity (Boots et al., 2002; 
Boots et al., 2007; Kalyanaraman et al., 1987; Moore et al., 1988; O'Brien, 1991). 
The toxicity of antioxidant flavonoids emerges when they adduct thiol groups of 
vital cellular proteins. Actually, it is not the flavonoid itself that displays this thiol 
toxicity but the oxidized form generated when the flavonoid exerts its antioxidant 
activity. The scavenging activity protects against the unselective reactivity of the 
radical, but can subsequently selectively induce toxicity to vital cellular compounds 
containing SH-groups. Ascorbic acid—an important antioxidant in the antioxidant 
network which has the potential to react with the oxidized flavonoids—might 
circumvent this thiol toxicity and as a bonus recycle the flavonoid (Jacobs et al., 
2010). 
In this study the reactivity of two structurally closely related flavonoids quercetin 
and its 4’-O-methylated metabolite, tamarixetin have been investigated towards the 
thiol containing protein, creatine kinase (CK). It was found that the quinones of 
quercetin and tamarixetin are indeed thiol reactive. Our mass spectrometry data 
confirm adduction and indicate that both quinones react with cysteine 146 of CK, 
which is known to be essential for enzyme function (Zhao et al., 2006). The relative 
intensity of the adduct between CK and tamarixetin detected by MALDI-TOF was 
lower than that of quercetin and CK under the same experimental conditions. In 
accordance to these results, the activity of CK was less attenuated by tamarixetin 
quinone than quercetin quinone. This shows that the tamarixetin quinone is less thiol 
toxic than the quercetin quinone. 
Ascorbate is able to efficiently protect against the inactivation of CK by oxidized 
tamarixetin. Remarkably, ascorbate only slightly protected against the inactivation 
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of CK by the quercetin quinone. Apparently, the oxidized tamarixetin prefers to 
react with ascorbate instead of creatine kinase. Ascorbate is able to recycle the 
tamarixetin quinone to its parent flavonoid. The oxidized ascorbate formed in this 
redox reaction can, on its turn, be reduced, e.g. by dehydroascorbate reductase that 
uses NADH as cofactor. In this way the reactivity of the radical is completely 
neutralized, tamarixetin is recycled and the enzyme inactivation is prevented. These 
results  show that  the  O-methylation on the 4’-O position of quercetin ablates thiol 
toxicity.  
The difference between quercetin and tamarixetin in directing the reactivity, 
originates from a minor change in the chemical structure and can be explained by 
Pearson’s HSAB (Hard and Soft Acids and Bases) concept (Pearson, 1963). 
Oxidized tamarixetin contains a positively charged group that has a relatively high 
polarity, which reflects in a high LUMO (Lowest Unoccupied Molecular Orbital) 
energy (21.33 kJ/mol) (Moalin et al., 2012) (Figure 1). This makes oxidized 
tamarixetin a ‘hard’ electrophile which prefers to react with ascorbate, a ‘hard’ 
nucleophile. This is reflected in a high value of the competition between ascorbate 
and thiols (CAT), i.e., 14.5 ± 3.8 (Moalin et al., 2012). The CAT was determined by 
dividing the rate of reaction of the oxidized flavonoid with ascorbate by the rate of 
reaction of the oxidized flavonoid with the thiol GSH.  
The quercetin quinone lacks this highly polar group and the carbonyl groups of 
oxidized quercetin are positioned at maximal distance. Therefore the LUMO of 
oxidized quercetin is distributed over all the phenolic rings which gives rise to a low 
LUMO energy (í112.14 kJ/mol) (Moalin et al., 2012). Consequently, oxidized 
quercetin is a relatively “soft” electrophile and will prefer to react with ‘soft’ 
nucleophiles as the thiol group of GSH (the CAT of oxidized quercetin is 0.04 ± 
0.03) (Moalin et al., 2012) and as shown in the present study also with protein thiols. 
 
The present study addresses the selective toxicity of flavonoid antioxidants. 
Flavonoids pick up the reactivity of radicals and act as a pivot to channel the 
reactivity (Figure 5). Quercetin quinone channels its reactivity selectively towards 
thiol toxicity. The low but selective reactivity of oxidized antioxidants that directs 
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the reactivity to a focal point (in this case thiols) has been implicated in the toxicity 
of antioxidants (Bast and Haenen, 2002). The selective reactivity of tamarixetin 
quinone directs the reactivity towards ascorbate in the antioxidant network. This 
might explain why tamarixetin is found to be less toxic than quercetin in cells 
(Spencer et al., 2003). Apparently, the introduction of only one methyl group in 
quercetin, giving tamarixetin, leads to a remarkably high reduction of the selective, 
thiol toxicity.  
 
 
Figure 5. Overview of the difference in thiol toxicity between quercetin and tamarixetin. 
Tamarixetin and quercetin both protect against radical toxicity. The oxidized products that 
arise  in  this  process  (QQ  and  TQ)  are  thiol  reactive.  In  the  presence  of  ascorbate  TQ  
preferentially passes its reactivity to ascorbate. An extra advantage is that ascorbate recycles 
TQ to the parent compound. 
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Supplemental data 
 
Ascorbate prevented the net consumption of tamarixetin. The prevention of the 
oxidation of tamarixetin by ascorbate was checked. 
 
Materials and methods 
 
Spectrophotometric analysis 
Tamarixetin (50 µM) was oxidized by H2O2 (50 µM) and HRP (3.2 nM) in 145 mM 
potassium-phosphate buffer (pH 7.4). The incubation mixtures were analyzed 
spectrophotometrically in presence or absence of ascorbate (50 µM). The incubation 
mixture of ascorbate (50 µM) with (50 µM) and HRP (3.2 nM) in 145 mM 
potassium-phosphate buffer (pH 7.4) was also analyzed. All spectra were recorded 
from 220 to 600 nm. The UV/Vis scans were started 30, 90, 150, 210, 270 sec after 
the addition of HRP. 
 
Results 
 
Spectrophotometric analysis of the oxidation of tamarixetin 
The tamarixetin concentration decreased in the incubation mixture containing 
HRP/H2O2. Addition of 50 µM ascorbate to the incubation mixture shows no net 
consumption of tamarixetin (figure 6A and 6B). HPLC analysis of the incubation 
mixtures confirmed that no tamarixetin was consumed in the presence of ascorbate 
(data not shown). In the incubation ascorbate was consumed, evidenced in the 
spectrum by the decrease of the absorption at 270 nm. When tamarixetin was 
omitted from the incubation mixture, the ascorbate concentration did not change 
(figure 6C). For quercetin similar results have been reported (Moalin et al., 2012).. 
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Figure 6. Spectrophotometrical analysis of the incubation mixture containing 50 µM 
tamarixetin, 50 µM H2O2  and 3.2 nM HRP (A). The same experiment was carried out in the 
presence of 50 µM ascorbate (B). Ascorbate was incubated with 50 µM H2O2 and 3.2 nM 
HRP (C).  The UV/Vis scans were recorded 30, 90, 150, 210, 270 sec after addition of HRP. 
The spectra of 50 µM H2O2 and 3.2 nM HRP, 50 µM tamarixetin and 50 µM ascorbate are 
shown (D).  
 
Conclusion  
 
Ascorbate did not inhibit the oxidation, but immediately reduced the oxidized 
tamarixetin. 
 
Chapter 3 
52 
References 
 
Bast, A., Haenen, G.R., 2002. The toxicity of antioxidants and their metabolites. 
Environmental Toxicology and Pharmacology 11, 251-258. 
Bast, A., Haenen, G.R., 2013. Ten misconceptions about antioxidants. Trends in 
Pharmacological Sciences 34, 430-436. 
Bjelakovic, G., Nikolova, D., Gluud, C., 2014. Antioxidant supplements and mortality. 
Current Opinion in Clinical Nutrition and Metabolic Care 17, 40-44. 
Boots, A.W., Haenen, G.R., den Hartog, G.J., Bast, A., 2002. Oxidative damage shifts from 
lipid peroxidation to thiol arylation by catechol-containing antioxidants. Biochimica et 
Biophysica Acta 1583, 279-284. 
Boots, A.W., Li, H., Schins, R.P., Duffin, R., Heemskerk, J.W., Bast, A., Haenen, G.R., 2007. 
The quercetin paradox. Toxicology and Applied Pharmacology 222, 89-96. 
Brevik, A., Rasmussen, S.E., Drevon, C.A., Andersen, L.F., 2004. Urinary excretion of 
flavonoids reflects even small changes in the dietary intake of fruits and vegetables. 
Cancer epidemiology, biomarkers & prevention 13, 843-849. 
Halliwell, B., 1996. Antioxidants in human health and disease. Annual Review of Nutrition 
16, 33-50. 
Ito, S., Kato, T., Fujita, K., 1988. Covalent binding of catechols to proteins through the 
sulphydryl group. Biochemical Pharmacology 37, 1707-1710. 
Jacobs,  H.,  Moalin,  M.,  Bast,  A.,  van  der  Vijgh,  W.J.,  Haenen,  G.R.,  2010.  An  essential  
difference between the flavonoids monoHER and quercetin in their interplay with the 
endogenous antioxidant network. PLoS One 5, e13880. 
Kalyanaraman, B., Premovic, P.I., Sealy, R.C., 1987. Semiquinone anion radicals from 
addition of amino acids, peptides, and proteins to quinones derived from oxidation of 
catechols and catecholamines. An ESR spin stabilization study. The Journal of Biological 
Chemistry 262, 11080-11087. 
Moalin, M., van Strijdonck, G.P., Bast, A., Haenen, G.R., 2012. Competition between 
ascorbate and glutathione for the oxidized form of methylated quercetin metabolites and 
analogues: tamarixetin, 4’-O-methylquercetin, has the lowest thiol reactivity. Journal of 
Agricultural and Food Chemistry 60, 9292-9297. 
Moore,  G.A.,  Weis,  M.,  Orrenius,  S.,  O'Brien,  P.J.,  1988.  Role  of  sulfhydryl  groups  in  
benzoquinone-induced Ca2+ release by rat liver mitochondria. Archives of Biochemistry 
and Biophysics 267, 539-550. 
O'Brien, P.J., 1991. Molecular mechanisms of quinone cytotoxicity. Chemico-biological 
interactions 80, 1-41. 
Pearson, R.G., 1963. Hard and Soft Acids and Bases. Journal of the American Chemical 
Society 85, 3533-3539. 
Reddy, S., Jones, A.D., Cross, C.E., Wong, P.S., Van Der Vliet, A., 2000. Inactivation of 
creatine kinase by S-glutathionylation of the active-site cysteine residue. The Biochemical 
Journal 347 Pt 3, 821-827. 
Spencer, J.P., Kuhnle, G.G., Williams, R.J., Rice-Evans, C., 2003. Intracellular metabolism 
and bioactivity of quercetin and its in vivo metabolites. Biochemistry Journal 372, 173-
181. 
Willcox, J.K., Ash, S.L., Catignani, G.L., 2004. Antioxidants and prevention of chronic 
disease. Critical Reviews in Food Science and Nutrition 44, 275-295. 
Zhao, T.J., Liu, Y., Chen, Z., Yan, Y.B., Zhou, H.M., 2006. The evolution from asparagine or 
threonine to cysteine in position 146 contributes to generation of a more efficient and 
stable form of muscle creatine kinase in higher vertebrates. The International Journal of 
Biochemistry & Cell Biology 38, 1614-162 
  
Chapter 4 
 
The antioxidant flavonoid monoHER provides 
efficient protection and induces the innate NRF2 
mediated adaptation in endothelial cells subjected 
to oxidative stress 
 
Kristien J.A. Lemmens, Mireille M.J.P.E. Sthijns, Wim J.F. van der Vijgh,  
Aalt Bast, Guido R.M.M. Haenen 
 
PharmaNutrition, 2014; 2(3): 69-74 
 
 
 
 
 
 
Chapter 4: The antioxidant 
flavonoid monoHER provides 
efficient protection and induces 
the innate NRF2 mediated 
adaptation in endothelial cells 
subjected to oxidative stress 
 
Chapter 4 
54 
Abstract 
 
Reactive oxygen species (ROS) can react with any cellular component leading to 
oxidative damage. As an adaptive response to ROS, cells activate NRF2 which 
enforces the endogenous antioxidant defense. 
Exogenous antioxidants directly neutralize the ROS and prevent the oxidative 
damage. This protection against ROS might backfire, because the adaptive response 
of the cell is prevented. 
The flavonoid monoHER efficiently scavenges ROS. In this study the effect of 
monoHER on the oxidative stress as well as the adaptive response was investigated. 
It was found that monoHER protected against oxidative stress caused in HUVECs 
by  H2O2,  while  monoHER did  not  prevent  the  induction  of  the  adaptive  response,  
including the nuclear translocation of NRF2 as well as the upregulation of HO-1 
gene expression. Remarkably, monoHER added to HUVECs which were not 
subjected to oxidative stress did not cause an adaptive response. 
The concept that emerges is that by scavenging ROS, the oxidized monoHER 
formed channels the reactivity selectively to thiol groups. Oxidized monoHER 
adducts KEAP1, which can set the innate NRF2 machinery into motion and enforce 
the endogenous antioxidant defense. In this way monoHER acts as a double-edged 
sword in cells subjected to oxidative stress; the antioxidant offers direct protection 
and induces adaptation.  
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Introduction 
 
Reactive oxygen species (ROS) belong to the most aggressive molecules produced 
in biology and can react with any cellular constituent ranging from DNA to proteins 
and lipids (Bast et al., 1991). This high, non-selective reactivity forms the basis of 
the toxicity of ROS. Cells are protected against ROS by antioxidants (Sies, 1993). 
When ROS production is enhanced, cells adapt by raising their protective 
antioxidant shield (Chaudiere and Ferrari-Iliou, 1999). Such a cellular flexibility is 
far more economical and efficient than continuously wearing a suit of armor against 
all possible threats (Sthijns et al., 2014). The ability to adapt to ROS is triggered by 
activation of the innate antioxidant machinery via gene expression through the 
Nuclear factor erythroid 2-related factor 2 (NRF2) pathway, which results in higher 
cellular levels of antioxidants and antioxidant enzymes (Kobayashi and Yamamoto, 
2006). 
Nutrition rich in antioxidants or antioxidants administered as supplement, 
nutraceutical or drug are also applied in an attempt to alleviate ROS damage (Boots 
et al., 2008; Rietjens et al., 2007; Vetrani et al., 2013). In this respect, the semi-
synthetic flavonoid antioxidant monoHER proved to be very effective. MonoHER is 
the most powerful antioxidant in the registered drug Venoruton® and displays 
excellent radical scavenging properties (Haenen et al., 1993; Lemmens et al., 2014). 
By scavenging, the damaging reaction of ROS with cellular compounds is 
prevented. In this way monoHER directly protects against cellular damage. 
However, the protection against ROS is expected to backfire because also the 
activation  of  the  innate  NRF2  pathway  might  be  prevented.  In  this  case,  the  
paradoxical consequence is that no protective adaptation is elicited because 
antioxidant administration prevents the endogenous defensive shield to be raised.  
The potentially paradoxical effect of antioxidants prompted us to investigate the 
effect of monoHER on the cellular adaptive response. Human Umbilical Vein 
Endothelial cells (HUVECs) were selected as a model since Venoruton® is used in 
the treatment of endothelial venous insufficiency (Cesarone et al., 2006). To induce 
oxidative stress, the cells were exposed to H2O2, which is a relatively stable ROS and 
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thus enabled us to impose a reproducible oxidative stress upon the cells. Besides, 
H2O2 is constantly formed by endothelial cells through various enzymatic systems, 
e.g. via superoxide radicals formed by NAD(P)H oxidase (NOX) which dismutate to 
H2O2. H2O2 easily crosses the cellular membrane through aquaporin channels (Miller 
et al., 2010). It can give rise to the highly toxic hydroxyl radicals.  
It was confirmed that monoHER protects against oxidative stress induced by H2O2. 
Remarkably, monoHER did not reduce the selective adaptation against oxidative 
stress.  
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Materials and methods 
 
Chemicals 
7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) was kindly provided by Novartis 
Consumer Health (Nyon, Switzerland). Hydrogen peroxide (H2O2), 2',7'-
dichlorofluorescein-diacetate (DCFH-DA), tert-Butylhydroquinone (T-BHQ), DL-
Dithiothreitol (DTT), sodium fluoride (NaF), sodium molybdate (Na2MoO4), 
Ethylenediaminetetraacetic acid (EDTA), Protease Inhibitor Cocktail, Hepes and 
horseradish peroxidase (HRP) were obtained from Sigma (St. Louis, MO, USA). 
Lysis buffer AM1 was obtained from Active Motif (Rixensart, Belgium). Trypsin 
was purchased from Promega (Madison, USA). Ammonium bicarbonate (ABC), 
acetonitrile (ACN), Į-cyano-4-hydroxycinnamic acid, 2',7'-dichlorofluorescein-
diacetate (DCFH-DA) and trifluoroacetic acid (TFA) were acquired from Sigma (St. 
Louis, USA). HUVECs, cell line-1730 was obtained from ATCC (Manassas, USA). 
Hank’s balanced salt solution (HBSS) was obtained from Invitrogen (Breda, The 
Netherlands). Kelch-like ECH-associated protein 1 (KEAP1) was purchased from 
Sino Biological Inc (Beijing, China). 
 
Cell culture 
HUVECs were cultured T75 coated culture flasks (Greiner Bio-one, Alphen a/d 
Rijn, The Netherlands) in Ham’s F12-K medium (Invitrogen, Breda, The 
Netherlands) supplemented with 10 % (v/v) fetal calf serum (FCS; Invitrogen, 
Breda, The Netherlands), 0.05 mg/ml endothelial cell growth supplement (ECGS; 
BD  Science,  Franklin  Lakes,  USA),  1  %  pen/strep  (Gibco,  Bleiswijk,  The  
Netherlands) and 0.01 mg/ml heparin (LEO Pharma, Ballerup, Denmark) in a 
humidified atmosphere containing 5 % CO2 and  95  %  air  at  37  °C.  The  maximal  
passage used was 24. 
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Measurement of intracellular oxidative stress 
The intracellular levels of oxidative stress were quantified by the fluorescence of 
DCF.  
Cells (4 X 104 per well) were plated in a 96-wells plate (Greiner Bio-one, Alphen 
a/d Rijn, The Netherlands) 24 h before the experiment. The cells were then 
incubated with 20 µM DCFH-DA in 5 % CO2 and 95 % air at 37 °C for 45 min. The 
cells were rinsed once with HBSS, after the medium with excess of DCFH-DA was 
removed. Subsequently the cells were incubated with 200 µM H2O2 and 0-50 µM 
monoHER in serum-free medium (Lemmens et al., 2014). The fluorescence (Ex 485 
nm, Em 538 nm) was determined on a microplate reader (Spectramax microplate 
reader, Molecular devices, Sunnyvale, USA) as a measure of oxidative damage. 
For the adaptation measurements, cells (4 X 104 per well) were plated in a 96-wells 
plate 24 h before the experiment. The cells were then incubated with serum-free 
medium and 200 µM H2O2 with  or  without  50  µM  monoHER  for  4  h.  After  a  
washing step with HBSS, the cells were treated with 20 µM DCFH-DA in 5 % CO2 
and 95 % air at 37 °C for 45 min. After the medium with excess of DCFH-DA was 
removed, the cells were rinsed once with HBSS and subsequently a solution 
containing 200 µM H2O2 was added followed by measuring the fluorescence of DCF 
on the microplate reader (Ex 485 nm, Em 538 nm). 
The  reaction  of  monoHER  with  H2O2 was examined by HPLC and 
spectrophotometrically (data not shown). MonoHER did not directly react with 
H2O2.   
 
Gene expression of heme oxygenase 1 
Real  Time  PCR  (qRT-PCR)  was  used  to  measure  the  gene  expression  of  heme  
oxygenase 1 (HO-1). Cells (2 X 105 per well) were plated in a 6 well-plate 24h 
before the experiment. After washing with HBSS, the cells were exposed to 0 or 50 
µM monoHER and 0-200 µM H2O2 for 3 h at 37 ÛC. After exposure cells were 
trypsinized. RNA was isolated with Qiazol lysis reagent (Qiagen, The Netherlands). 
The RNA concentration was measured using the NanoDrop System (Thermo 
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Scientific, Rockford, IL, USA). cDNA was prepared from 500 ng of RNA using the 
iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). Two step qRT-PCR was 
performed using 12.5 µl SensiMix SYBR & Fluorescein Kit (Bioline, London, UK) 
with 5 µl cDNA, and 2.5 µl of 100 µM of each primer (forward: 5’-
CTTCTTCACCTTCCCCAACA-3’, reverse: 5’-GCTCTGGTCCTTGGTGTCAT-
3’) in a 25 µl reaction mixture. The cycling conditions consisted of an initial 
denaturation at 95 ÛC for 10 minutes, followed by 40 alternating cycles at 95 ÛC and 
60 ÛC for 15 s and 45s, respectively, using the iCycler system (Bio-Rad, Hercules, 
CA). ȕ-actin (forward: 5’-CCTGGCACCCAGCACAAT-3’, reverse: 5’-
GCCGATCCACACGGAGTACT-3’) was used as housekeeping gene. Fold change 
was calculated relative to unexposed cells. 
 
Mass spectrometry 
MonoHER (50 µM) was oxidized by 50 µM H2O2 and 12.8 nM HRP in presence of 
0.5 mg/ml KEAP1 in 50 mM ABC buffer pH 7.4 for 15 min at 37 ÛC. KEAP1 (0.1 
mg/ml) was digested by trypsin during 2 hours at 37 °C. The digested samples were 
diluted 1:10 in 0.1 % TFA. After dilution, 1 µl of the digest and 1 µl of matrix 
solution (2.5 mg/ml Į-cyano-4-hydroxycinnamic acid in 50% ACN/0.1% TFA) was 
spotted on a 348-well-format target plate and air dried. Mass spectra were measured 
on the MALDI-TOF mass spectrometer (4800 MALDI-TOF analyzer; Applied 
Biosystems). The instrument was operated in positive reflector mode. Acquisition 
mass range was 800-3500 Da. 
 
Nuclear extraction  
HUVECs were resuspended in hypotonic buffer (5 mM NaF, 10 µM Na2MoO4, 0.1 
mM EDTA in 20 mM Hepes, pH 7.5), vortexed, and incubated on ice for 15 min. 
The suspension was centrifuged for 30 sec at 14000 g. The remaining nuclear pellets 
were resuspended in complete lysis buffer (1 µl 1 M DTT, 10 µl Protease Inhibitor 
Cocktail per ml Lysis Buffer AM1) and kept on ice for 30 min. The suspension was 
centrifuged (14,000 rpm, 10 min, 4°C), and the nuclear fraction was obtained. 
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Nuclear NRF2 measurement 
HUVECs (2 X 106 per well) were plated in a T75 culture flasks (Greiner Bio-one, 
Alphen a/d Rijn, The Netherlands) 24h before the experiment. Cells were exposed to 
50  µM monoHER with  or  without  H2O2 for  30  min.  As  positive  control  HUVECs 
were incubated with 25 µM t-BHQ.    
Nuclear NRF2 was determined in the nuclear extract of the cells using the TransAM 
NRF2 kit (Active Motif, Rixensart, Belgium). The TransAm NRF2 kit is based on 
ELISA. The kit contains a 96 well-plate on which oligonucleotide containing the 
ARE consensus binding site are immobilized. NRF2 in the nuclear extract 
specifically binds to this oligonucleotide. The primary antibody recognizes an 
epitope on NRF2 protein upon DNA binding. Addition of an HRP-conjugated 
secondary antibody provides a colorimetric readout quantified by 
spectrophotometry.  
Protein concentrations in the nuclear extracts were determined using the method of 
Bradford (Biorad, Veenendaal, The Netherlands) 
 
Statistics 
All experiments were performed at least in triplicate. Data are expressed as mean ± 
standard deviation (SD). Statistical analysis was performed using Student’s t-test.  
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Results  
 
Damage by and adaptation to oxidative stress by H2O2 
Two hundred µM of H2O2 induced oxidative stress in DCFH loaded HUVECs, 
deduced from the increase in fluorescence in time (figure 1A).  
To determine adaptation to oxidative stress, cells were first pretreated with H2O2, 
followed by a second exposure of the pretreated cells to H2O2. The oxidative stress 
induced by H2O2 in the pretreated cells was significantly less than that in not-
pretreated cells (figure 1A and 1C). Apparently H2O2 induces protection against a 
second challenge with H2O2 i.e. it induces an adaptive response to oxidative stress.  
 
Protection against and adaptation to oxidative stress by monoHER 
MonoHER was able to fully protect against the H2O2-induced oxidative stress in the 
cell (Figure 1B). To determine the effect of monoHER on the adaptation to oxidative 
stress, cells were first pretreated with the combination of H2O2 and monoHER. This 
pretreatment was followed by a second exposure of the pretreated cells to only 
H2O2. Again, the oxidative stress induced by H2O2 in the pretreated cells was 
significantly less than that in not-pretreated cells. Although monoHER fully 
protected against oxidative stress, monoHER did not impair the adaptive response to 
oxidative stress (Figure 1A and 1C).  
In a control experiment, cells were first pretreated with only monoHER, followed by 
a second exposure of the pretreated cells to H2O2. The oxidative stress induced by 
H2O2 in these pretreated cells was similar to that in not-pretreated cells (Figure 1A 
and 1C). Apparently, monoHER itself does not induce an adaptive response to 
oxidative stress.  
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Figure 1. Pretreatment of HUVEC’s with H2O2 and the combination of H2O2 with monoHER 
induces an adaptive protection against oxidative stress. Panel A shows intracellular oxidative 
stress in pretreated HUVEC’s induced by 200 µM H2O2.  The pretreatment for 4 h was with 
200 µM H2O2 (curve denoted with ’H2O2’); with 50 µM monoHER (‘monoHER’); with the 
combination of 200 µM H2O2 and 50 µM monoHER (‘monoHER + H2O2’); or without extra 
compounds (‘control’). Intracellular oxidative stress was measured for 30 min using DCF 
fluorescence as described in the materials and methods section. Panel B shows the 
concentration dependent protection by monoHER against oxidative stress induced by 200 µM 
H2O2 in HUVEC’s. Panel C depicts the adaptive response found after 30 minute incubation 
with  200  µM  H2O2 in  control  HUVEC’s  (‘control’);  in  HUVECs  pretreated  with  200  µM  
H2O2 (‘H2O2’); in HUVECs pretreated with 50 µM monoHER (‘monoHER’); in HUVECs 
pretreated with 200 µM H2O2 in combination with 50 µM monoHER (‘monoHER + H2O2’). 
In panel A a typical example is shown. For panel B and C at least three independent 
experiments were performed in quadruplicate and data are shown as mean ± SD (*p<0.05, ** 
p<0.01 vs. control). 
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Heme oxygenase-1 gene expression 
H2O2 significantly increased the HO-1 gene expression in HUVECs (Figure 2). 
MonoHER in combination with H2O2 also led to a significant increase in the HO-1 
gene expression, although this tended to be slightly less than that with H2O2 alone. 
MonoHER without H2O2 did not affect the HO-1 gene expression (Figure 2). 
 
 
Figure 2. HO-1 gene expression measured in HUVECs exposed to 0 or 50 µM monoHER and 
0-200 µM H2O2 for  3  h.  Bars  represent  fold  change  (2íǻǻCt) compared to unexposed cells. 
Data are shown as mean ± SD (n4). (*p <0.01 vs. 0 µM H2O2, 0 µM mH). 
 
Adduction of monoHER on KEAP1 
MonoHER oxidized in the presence of KEAP1 reduced the intensity of the peak of 
the native peptide fragment, LNSAECYYPER with a mass of m/z = 1344 measured 
by  MALDI-TOF.  Instead,  a  new  peptide  fragment  with  a  mass  of  m/z = 1996 
emerged (Figure 3). The increment of the mass of the fragments corresponds to the 
molecular weight of the quinone of monoHER (652 Da). This indicates that the 
quinone formed by the oxidation of monoHER adducts KEAP1. 
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Figure 3. Adduction of KEAP1 by oxidized monoHER. MALDI-TOF analysis of isolated 
KEAP1 (0.1 mg/ml) incubated with 50 µM monoHER, 1.6 nM HRP and 50 µM H2O2, after 
trypsin digestion. The control spectrum of KEAP1 displayed a peak at m/z 1344 and no peak 
at m/z 1996. The incubation mixture with monoHER showed a peak at m/z 1996 which 
corresponds to the mass of the adduct of the monoHER quinone (652 Da) on the peptide with 
mass m/z 1344, whereas the peak at m/z 1344 decreased.  
 
NRF2 translocation 
Incubation of HUVECs with 200 µM H2O2 induced translocation of NRF2 to the 
nucleus. Also incubation with monoHER in combination with H2O2 resulted in the 
translocation of NRF2 to the nucleus, whereas incubation with only monoHER did 
not do so. (Figure 4). The positive control, t-BHQ did induce translocation of NRF2 
to the nucleus. 
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Figure 4. Induction of nuclear NRF2 in HUVEC’s by monoHER in combination with H2O2. 
HUVEC’s were exposed to 200 µM H2O2 or 50 µM monoHER ± 200 µM H2O2 for 30 min. t-
BHQ (25 µM) was used as positive control. NRF2 was measured in the nuclear extracts. At 
least three independent experiments were performed and data are shown as mean ± SD 
(*p<0.05 vs. basal level). 
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Discussion 
 
ROS possess an extreme high chemical reactivity and are therefore capable of 
damaging virtually any cellular component, which will eventually lead to toxicity 
(Bast et al., 1991). Enhanced ROS production stimulates the endogenous antioxidant 
defense system and enforces the innate protection against ROS toxicity (Chaudiere 
and Ferrari-Iliou, 1999). This cellular flexibility adapts cells to better withstand 
emerging oxidative stress. 
Numerous exogenous antioxidants directly protect by scavenging free radicals. It is 
well documented that this can directly offer an excellent protection against ROS 
damage (Boots et al., 2008; Lemmens et al., 2014; Rietjens et al., 2007). However, 
the protection by this mechanism might backfire because not only the damage but 
also the adaptive response might be prevented. The antioxidants take away the ROS 
that pull the trigger for raising the cellular protective shield. In the present study, the 
effect of the flavonoid antioxidant monoHER on the adaptive response is therefore 
examined.   
Oxidative stress was induced in HUVECs by H2O2. Our results show that 
pretreatment with H2O2 also enforces the protection of the cells against oxidative 
stress. This was concluded from the experiments in which cells were first pretreated 
with H2O2, followed by a second exposure of the pretreated cells to H2O2. The 
oxidative stress induced by H2O2 in the pretreated cells was significantly less than 
that in not-pretreated cells. Apparently, an adaptive response to oxidative stress is 
induced by activating the innate antioxidant defense system.  
The molecular mechanism behind the adaptation involves activation of the NRF2 
pathway. This is initiated by ROS-induced damage to KEAP1, the inhibitor of NRF2 
(Itoh et al., 2010). The ROS damaged KEAP1 dissociates from its complex with 
NRF2. Upon this dissociation, NRF-2 translocates to the nucleus. NRF2 is a 
transcription factor which activates the expression of Antioxidant Responsive 
Elements (ARE), such as antioxidant and detoxifying enzymes e.g. HO-1 (Itoh et al., 
1997; Itoh et al., 2004; Rushmore et al., 1991).  Due to the activated NRF2 pathway, 
the cell upgrades its protective shield against oxidative stress. The activation of this 
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pathway in the HUVECs by H2O2 is evidenced by the translocation of NRF2 to the 
nucleus, the induced HO-1 gene expression, and the adaptation of the cells to the 
second oxidative stress assault (Figure 5). This adaptation equates to the concept of 
hormesis: exposure to a damaging compound raises a specific protective shield 
(Sthijns et al., 2014). 
MonoHER possesses excellent antioxidant properties. This was confirmed in the 
present study, as monoHER was able to fully protect HUVECs against the induced 
oxidative stress. MonoHER owes this activity to its strategic location (i) on a 
molecular level, (ii) on a supramolecular level and (iii) on a cellular level (Lemmens 
et al., 2014). On the cellular level monoHER is localized in the endothelial and 
smooth muscle cells of the vascular wall where it appears to be retained 
(supplemental data), and where the protective effect of the monoHER containing 
preparation Venoruton® is due (Neumann et al., 1992).  
On the molecular level, monoHER is also exactly at the right location. The H2O2 
used can produce intracellular oxidative stress by reacting with iron to generate the 
extremely reactive OH-radical in a Fenton reaction. In the present study we 
confirmed that monoHER, already at a very low concentration (0.01-1 µM), can 
directly protect against the oxidative stress. This efficient protection can be 
explained by site-specific scavenging. Essential for this activity is that monoHER 
can chelate iron. The result of this chelation is that monoHER is present at the site of 
the radical formation, i.e. the iron ion. This enables monoHER to immediately 
scavenge newly formed radicals. By this site-specific scavenging, monoHER is able 
to prevent damage to critical biomolecules such as lipids, proteins or DNA, despite 
the high reactivity of the radical (Lemmens et al., 2014). 
Last, but not least is that monoHER is located on the supramolecular level at a 
pivotal position in the antioxidant network. Due to the site-specific scavenging, 
monoHER is the first molecule to react with the generated radicals. In the 
scavenging reactions, monoHER donates electrons or hydrogen atoms to the radicals 
involved. The radical is converted into a relatively stable non-radical, e.g. the 
hydroxyl radical becomes H2O.  MonoHER  takes  over  part  of  the  reactivity  of  the  
radical and is oxidized to a semi-quinone radical and monoHER quinone (Bast and 
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Haenen, 2002; Jacobs et al., 2009). Fortunately, the body is endowed with an 
intricate network of antioxidants that can react with oxidized monoHER. MonoHER 
quinone preferentially reacts in a redox reaction with ascorbate, and monoHER is 
recycled to scavenge radicals once again (Jacobs et al., 2010).  
Oxidized monoHER also reacts with thiols, evidenced by the formation of a GSH-
monoHER adduct after monoHER administration to human volunteers (Jacobs et al., 
2009). Our mass spectrometry data confirm this thiol reactivity, since oxidized 
monoHER adducts the KEAP1 peptide fragment LNSAECYYPER with cysteine 
489. This cysteine residue is situated in the NRF2 binding domain of the protein 
(Holland and Fishbein, 2010; Itoh et al., 1999). A consequence of the adduction is 
that the innate NRF2 machinery is set in motion and that via gene expression levels 
of endogenous antioxidant enzymes are increased. Indeed, the present study 
demonstrated that the combination of H2O2 and monoHER leads to translocation of 
NRF2 to the nucleus and the induction of the gene expression of HO-1, which 
cumulates in an adaptive upgrading of the protection against oxidative stress (Figure 
2 and 4 and illustrated in figure 5). 
Interestingly, monoHER itself did not induce an adaptive response in the HUVECs. 
The explanation is that monoHER itself lacks thiol reactivity. t-BHQ and acrolein, 
compounds that are thiol reactive themselves, were found to directly activate the 
NRF2 machinery (Arinze and Kawai, 2005; Kwak et al., 2003). For monoHER to do 
so, it first needs to be converted into a thiol reactive oxidation product. This happens 
when monoHER scavenges radicals. Thus, when monoHER acts as a free radical 
scavenger and becomes a thiol reactive quinone, it successively activates the 
endogenous antioxidant network. In this way the antioxidant acts as a double-edged 
sword; it offers direct protection as well as indirect protection. This explains why 
monoHER prevents the oxidative stress provoked by H2O2, and also induces the 
adaptive response. This dual action puts the protective effect of antioxidants like 
monoHER on a higher level. 
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Figure 5. Overview of the protective effect of monoHER against ROS toxicity and the 
induction of the adaptive response of the cell. ROS induce toxicity and activate the NRF2 
pathway which gives rise to an adaptive response in the cell. MonoHER protects by 
scavenging the ROS toxicity but does not prevent the adaptive response in the cells. The 
monoHER quinone formed during scavenging selectively adducts KEAP1 and activates the 
NRF2 pathway. 
 
This molecular mechanism does not only result in a very potent antioxidant activity, 
it also ensures that monoHER will act selectively in a condition of oxidative stress. 
The unbalanced ROS production found during oxidative stress is mandatory for the 
formation of the thiol reactive quinone of monoHER. This will selectively activate 
the NRF2 pathway in cells subjected to oxidative stress. This selectivity is 
substantiated by the observation that monoHER itself did not induce an adaptive 
response in the HUVECs, while the combination of monoHER with H2O2 did.  
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We conclude that H2O2 causes oxidative stress in HUVECs but adapts the cells by 
raising the antioxidant shield to withstand new assaults. MonoHER itself does not 
induce adaptation under control conditions. MonoHER efficiently protects against 
the oxidative stress caused by H2O2 and, surprisingly, still induces the adaptive 
response of the cells subjected to oxidative stress. It appears that the antioxidant 
flavonoid monoHER provides efficient protection and induces the innate NRF2 
mediated adaptation in HUVECs subjected to oxidative stress.
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Supplemental data 
 
The localization of monoHER in carotid arteries was studied by two photon laser 
scanning microscopy (TPLSM). 
 
Materials and methods 
 
The animal protocol was approved by the Ethics committee for Animal Experiments 
of Maastricht University (Maastricht, The Netherlands).  
Two C57BL/6J mice, obtained from Maastricht University, were housed under 
standard conditions. The animals were allowed to adapt to the laboratory housing 
conditions for two weeks before the experiment was started. The animals were 
allowed to eat and drink water ad libitum. One mouse was injected with monoHER 
subcutaneously (500 mg/kg) every day during 21 days to obtain a chronic exposure. 
The other mouse received saline according to the same injection scheme. The mice 
were sacrificed 24 h after the last injection. The isolated carotid arteries were filled 
with HBSS before two photon laser scanning microscopy (TPLSM). 
 
The carotid arteries were imaged using TPLSM (TCS SP5 CFS AOBS with a 
Coherent: Chameleon Ultra II.  ir. 140 fs pulsed laser system >300 KW, for 2 photon 
excitation at 800 nm, Emission filter: 510 - 580 nm) (Leica Microsystems, Wetzlar, 
Germany). A HCX APO L 20.0 x 1.00 water objective (WD = 2.0 mm) was used. 
Images were obtained using LAS-AF SP5 software. No further image processing 
was carried out. 
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Results 
 
Injection of monoHER in a mouse led to accumulation of monoHER in the wall of 
the carotid artery. The artery displayed fluorescence in the nuclei of the endothelial 
and smooth muscle cells (Figure 6). Similar results were obtained in carotid arteries 
incubated with monoHER (Lemmens et al., 2014). 
 
 
Figure 6. Localization of monoHER in the carotid artery. Two Photon Laser Scanning 
Microscopy imaging of longitudinal cross-sections of an intact carotid artery from a mouse 
injected with vehiculum (A) or with monoHER (B) isolated 24 h after the last injection. The 
elastic lamina autofluoresce in the same wavelength range as monoHER, i.e. emission 510-
580 nm, and are therefore visible.  The carotid artery from the mouse injected with monoHER 
shows fluorescence in the nuclei of the endothelial cells (round spots) and smooth muscle 
cells (elongated spots). 
 
Conclusion 
 
MonoHER localizes in the nuclei of the endothelial and smooth muscle cells in the 
carotid artery. 
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Abstract 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease. An 
evidence-based pharmacological treatment for NAFLD is still lacking, but 
flavonoids have shown therapeutic potential. The present study was designed to 
investigate the effect of the flavonoid monoHER on the onset of NAFLD in Ldlr-/- 
mice on a high-fat and high-cholesterol diet. The focus was put on the effect on 
oxidative stress as well as the adaptive response. Wild type mice served as a control 
and the effect of monoHER was compared to that of a placebo.  
In the Ldlr-/- group, monoHER provided only a mild protection against oxidative 
stress. In the placebo Ldlr-/- group an adaptive response elicited by the NRF2 
antioxidant defense system was observed, evidenced by a higher HO-1 and Gpx3 
gene expression, as well as an increased redox status, evidenced by the higher 
GSH/GSSG ratio. In the monoHER treated Ldlr-/- group both the adaptive response 
as  well  as  the  increase  in  redox  status  tended  to  be  higher,  although  this  did  not  
reach significance on a group level. Unexpectedly, a strong within animal 
relationship was found that links a high adaptive response to a low redox status in 
the monoHER Ldlr-/- group. This correlation was absent in the placebo and wildtype 
group.  
The concept that emerges is that a thiol-reactive oxidation product of monoHER, 
formed during oxidative stress, selectively induces the NRF2 pathway and enforces 
the endogenous antioxidant shield, to provide protection against NAFLD. 
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Introduction  
 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in 
Western countries affecting 20-30% of the general population, and this percentage is 
still on the rise. NAFLD includes a spectrum of liver disorders ranging from 
steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and 
hepatocellular carcinoma (Berlanga et al., 2014). Up to date, no evidence-based 
pharmacotherapy  is  available  for  NAFLD.  To  find  a  way  to  prevent  NAFLD,  the  
molecular processes involved in the onset of the disease should be controlled.  
One of the hallmarks in the etiology of NAFLD is oxidative stress (Koek et al., 
2011; Rolo et al., 2012). During oxidative stress, the unbalanced production of 
reactive oxygen species (ROS) results in damage to virtually any cellular 
component, which explains the prominent role of ROS in NAFLD. However, ROS 
also destruct KEAP1, the inhibitor protein of NRF2. NRF2 serves as a master redox 
switch which turns on the expression of endogenous antioxidant genes e.g. HO-1 
and Gpx3 (Itoh et al., 2004) and ultimately increases the cellular redox potential. 
Consequently, cells adapt to ROS through this potent feedback mechanism which 
enforces the protection against ROS. This fits in the current concept that health is a 
dynamic process characterized by the ability to adapt to challenges on a delicate 
homeostasis (2009).  
In this concept of health, drugs are bioactive compounds that help to restore and 
enforce homeostasis. Numerous studies have demonstrated the beneficial effect of 
flavonoids - a group of antioxidant bioactives commonly found in our diet - in 
animal models of NAFLD (van de Wier et al., 2014). Among the flavonoids, 7-
mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) appears to be one of the most 
promising ones for treatment of NAFLD (van de Wier et al., 2014). This flavonoid 
is the main ingredient of Venoruton, a drug that has been used for several decades in 
the treatment of venous insufficiency. MonoHER displays excellent antioxidant 
activity (Lemmens et al., 2014a; Lemmens et al., 2014b), has a relatively high 
bioavailability and is relatively safe (van de Wier et al., 2014). Based on these 
favorable characteristics monoHER was selected for this study. 
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To evaluate its efficacy, the effect of monoHER on oxidative stress and the adaptive 
response during the onset of NAFLD was determined in an animal model. Previous 
studies have shown that Ldlr-/- mice on a high-fat and high-cholesterol diet are a 
suitable model to study the development of NAFLD (Bieghs et al., 2012). Wild type 
mice  served  as  control  and  the  effect  of  monoHER  was  compared  to  that  of  a  
placebo. The effect was evaluated on three levels, namely the direct damage by 
ROS, the NRF2-induced gene expression and the adaptive response on the cellular 
redox status.   
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Material and methods 
 
Animals and treatment 
Female C57BL/6J wildtype mice (WT mice) were obtained from Jackson 
laboratories (Bar Harbor, Maine, USA) and bred at the breeding facility of 
Maastricht University. Female LDL-receptor knockout mice on a C57BL/6J 
background (Ldlr-/- mice) were bred at the breeding facility of Maastricht University. 
Mice were maintained in a temperature- and light-controlled facility and were 
permitted ad libitum consumption of water and chow. At the age of 13 weeks, all 
mice started a high-fat and high-cholesterol diet (HFD) (D11012302) (Research 
Diets, New Brunswick, USA) with 0.2% cholesterol and fat derived from palm oil, 
which provided adequate levels of vitamins (Vitamin Mix V10001, Research Diets, 
New Brunswick, USA). The mice were divided in four experimental groups: WT 
mice treated with placebo (n=12), WT mice treated with MonoHER (n=12), Ldlr-/- 
mice treated with placebo (n=12) and Ldlr-/- mice treated with MonoHER (n=12). 
MonoHER was administered daily subcutaneously at a dosage of 500 mg/kg of body 
weight (25 ȝl per g of body weight). With this dose, monoHER provided complete 
protection against doxorubicin-induced cardiotoxicity in mice (van Acker et al., 
1995). Daily subcutaneous injection of a physiological saline solution (25 ȝl per g of 
body weight) was used as placebo. Mice were weighed every three days and food 
intake was recorded for every 2 mice housed together. Diet and treatment were 
continued for 3 weeks, after which mice were anaesthetized with 0.05 mg/kg 
buprenorphine and isoflurane 0.4 l/min and sacrificed by exsanguination from the 
vena cava. The liver was removed and divided in different parts for further 
investigation. Part of the large left lobe was used for RNA isolation. 
 
Direct damage by ROS  
To determine the direct damage by ROS, oxidative damage to poly-unsaturated fatty 
acids in the liver was determined by measuring malondialdehyde (MDA) formation. 
Liver homogenate (250 mg liver/ml) was prepared in 145 mM potassium phosphate 
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buffer (pH 7.4). MDA was determined by reaction of MDA with thiobarbituric acid 
(Haenen and Bast, 1983) and quantified by HPLC (Lepage et al., 1991).  
 
Cellular redox status 
The cellular redox status was assessed by quantifying the GSH/GSSG ratio. Total 
glutathione content and glutathione disulfide (GSSG) were measured according to 
the enzymatic recycling method (Julicher et al., 1988) quantifying the conversion of 
DTNB into TNB spectrophotometrically at 412 nm and 37 °C. The GSH/GSSG-
ratio was calculated from the content of GSSG and total glutathione. 
 
Activation of the NRF2 antioxidant defense system 
An  adaptive  response  by  the  NRF2  antioxidant  defense  system  was  evaluated  by  
measuring HO-1 and Gpx3 gene expression in the liver. Liver parts that were stored 
in RNAlater® at -80°C were used for RNA isolation using miRNeasy Mini Kit with 
DNase treatment (Qiagen, Venlo, The Netherlands) according to protocol. Isolated 
RNA was converted into cyclic DNA (cDNA) using iScript cDNA synthesis kit 
(Bio-rad, Veenendaal, The Netherlands). Two step qRT-PCR was performed using 
12.5 µl SensiMix SYBR & Fluorescein Kit (Bioline, London, UK) with 5 µl cDNA, 
and 300 nM of each primer (HO-1: forward: 5’-GAGCCTGAATCGAGCAGAAC-
3’, reverse: 5’-CCTTCAAGGCCTCAGACAAA-3’, Gpx3: forward: 5’-
CATCCTGCCTTCTGTCCCT-3’, reverse: 5’-ATGGTACCACTCATACCGCC-3’) 
in a 25 µl reaction mixture. PCR was conducted as follows: denaturation at 95°C for 
10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 45 seconds. 
Following PCR, a melting curve (60–95°C) was produced for product identification 
and purity check. Gapdh (Glyceraldehyde-3-phosphate dehydrogenase) and Ywhaz 
(Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, 
Zeta Polypeptide) (Eurofins, Breda, The Netherlands) were used as housekeeping 
genes (Bruce et al., 2012). An average value of the expression of the house keeping 
genes Gapdh (forward: 5’-TTGATGGCAACAATCTCCAC-3’, reverse: 5’-
CGTCCCGTAGACAAAATGGT-3’) and Ywhaz (forward: 5’-
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CAGCAGATGGCTCGAGAATA-3’, reverse: 5’-
GAAGCATTGGGGATCAAGAA-3’) was used for the calculation of the ǻCt-
value. The validity was confirmed by the high within-animal correlation between the 
values of Gapdh and Ywhaz (R2= 0.8041). Primer sequences are listed in Table 1. 
Data were analyzed using the MyIQ software system (BioRad, Veenendaal, The 
Netherlands) and were expressed as relative gene expression (fold change) using the 
2ǻǻCt method. 
 
Statistics 
Data were analysed with GraphPad Prism 5 (Graphpad software, CA, USA). Values 
presented in the study are expressed as mean ± standard deviation (SD). The 
relationships of the GSH/GSSG ratio with HO-1 and Gpx3 gene expression were 
evaluated using linear correlation. Differences between groups were analyzed using 
the Kruskal-Wallis test. Post-hoc testing was performed using the Mann-Whitney U-
test with Bonferroni correction. A P < 0.05 was considered to be statistically 
significant, P < 0.1 and > 0.05 as indicating a trend. 
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Results and discussion 
 
There were no significant differences in food intake between the groups 
(Supplemental data).  Initial and also final body weight and liver weight did not 
differ between the groups. In the placebo treated Ldlr-/- mice  only  a  trend towards  
increased liver/total body weight-ratio compared to placebo treated WT mice was 
observed, confirming that in the relatively short period of 3 weeks only the onset of 
NAFLD was studied. 
A trend was seen towards a higher average level of lipid peroxidation (MDA) in 
Ldlr-/- mice compared to WT mice (Figure 1A), although this difference failed to 
reach significance. No pronounced effect of monoHER against ROS damage was 
seen. This could be due to the relatively large variation in the results. An explanation 
for the relatively large variation is that the onset of the disease is examined. At the 
onset of the disease, the effects are relatively small compared to the biological 
variation. Moreover, the time course of the gradual progression into a clear 
manifestation of the disease will vary between the mice studied. The effect was only 
examined at a single point in time, and this also contributes to a relatively large 
inter-animal variation. The relatively large variation might explain that only a mild 
effect was found on a group level. 
The general protective effect of monoHER against oxidative stress can be explained 
by its ability to scavenge ROS (Lemmens et al., 2014b). However, scavenging might 
block the activation of the innate NRF2 pathway by ROS. In this case, the 
paradoxical consequence is that no protective adaptation is elicited because 
antioxidant administration prevents the endogenous defensive shield to be raised.  
This has fueled the vexed dispute on the use of antioxidants in the prevention and 
treatment of diseases (Bast and Haenen, 2013). However, in the present study it was 
found that monoHER did not block the adaptive response; in contrast, a trend 
towards further increased levels of HO-1 and Gpx3 gene expression was found with 
monoHER (Table 1). 
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Figure 1. Direct damage by ROS (determined as MDA formation) and cellular redox 
status (determined as GSH/GSSG ratio). In panel A and B the Tukey Box-plot is shown of 
MDA  and  GSH/GSSG  ratio,  measured  in  liver  tissue  of  WT  and  Ldlr-/- mice treated with 
placebo or monoHER. * P < 0.01. The outlier is included in the statistical evaluation. Panel C 
and D show the within-animal linear correlation between the cellular redox status and the 
NRF2-dependent adaptive response during the onset of NAFLD in the liver of Ldlr-/- mice. In 
the group treated with monoHER, the adaptive response, expressed as HO-1 (C)  and  Gpx3 
(D) gene expression, was relatively high at a low cellular redox status, indicated by a low 
GSH/GSSG ratio (P = 0.012 and P = 0.046 respectively).  This relationship is lacking in the 
placebo group. 
 
The higher NRF2 induced gene expression in Ldlr-/- mice  (Table  1)  was  
corroborated by the adaptive response on the cellular redox status (figure 1B). In 
Ldlr-/- mice monoHER also tended to further increase the GSH/GSSG-ratio in Ldlr-/- 
mice (Figure 1B).  
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That monoHER does not inhibit the adaptive response, can be explained by the 
formation of a thiol reactive oxidation product of monoHER when it scavenges 
radicals. This oxidation product of monoHER selectively adducts a cysteine residue 
in KEAP1 and this adduction of KEAP1 induces the adaptive response (Lemmens et 
al., 2014a). In fact, the rather unspecific reactivity of ROS that does not only destroy 
KEAP1 but also vital cellular components such as other proteins and DNA, is 
exchanged for the much more selective reactivity of the oxidized product of 
monoHER towards KEAP1 (Lemmens et al., 2014a). 
 
Table  1.  Activation  of  the  NRF2  antioxidant  defense  system.  HO-1 and Gpx3 gene 
expression was measured to evaluate the activation of the NRF2 antioxidant defense system in 
liver tissue of WT and Ldlr-/- mice treated with placebo (p) or monoHER. Data represent fold 
change compared to WT + p group. Mean ± SD is shown. * P < 0.05 compared to WT + p 
group, ** P < 0.05 compared to WT + monoHER group 
Gene WT  
p 
WT  
monoHER 
Ldlr-/-  
p 
Ldlr-/- 
monoHER 
HO-1 1.00±0.40 0.98±0.29 2.27±1.48* 2.66±1.25** 
Gpx3 1.00±0.57 1.43±0.51 2.21±1.01* 3.02±1.09** 
 
MonoHER administration did not induce an adaptive response in the WT animals. In 
this respect, it should be noted that monoHER itself lacks thiol reactivity. MonoHER 
first needs to be converted into a thiol-reactive oxidation product to induce an 
adaptive response (Lemmens et al., 2014a). This conversion happens when 
monoHER scavenges radicals. In the control animals the generation of the thiol-
reactive oxidation product will be relatively low. Therefore, no adaptive response as 
a result of monoHER administration is expected in the control animals.  
The formation of the thiol-reactive oxidation product, exclusively during oxidative 
stress can be seen as a form of targeting. It results in an adaptive enforcement of the 
antioxidant system when this is needed. Interestingly, in the monoHER treated   
Ldlr-/- mice also evidence for targeting was seen. We expected that monoHER would 
activate NRF2 which subsequently would results in a higher cellular redox status. 
This was indeed found, but to our surprise in the monoHER group an improved 
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redox status was associated with a relatively low NRF2 activation. Apparently, 
monoHER administration results in a relatively potent adaptation.  In the monoHER 
treated Ldlr-/- mice NRF2 activation was relatively high at a low GSH/GSSG ratio. 
This indicates that a relatively low redox status, i.e. a low GSH/GSSG ratio, tends to 
increase NRF2 activation in the monoHER treated Ldlr-/- group. Moreover, in the 
liver of animals that have a relatively high GSH/GSSG ratio, no evidence for further 
stimulation of NRF2 by monoHER was seen, indicating that in the animals that have 
adapted, no further adaptation is needed (Figure 1C and 1D). In retrospect, this 
relationship is more logical than the anticipated high redox status when the adaptive 
response is high, i.e. that in the adapted animals more adaptation is needed, which of 
course  is  not  necessary.  No  correlation  was  found  in  the  corresponding  placebo  
group and in both control groups with WT mice probably because there was no 
substantiated adaptation. The higher level of adaptation and the reported correlation 
with NRF2 activation in monoHER treated Ldlr-/- mice  was  absent  in  the  other  
group. This indicates that monoHER has promoted the adaptive response.   
In the present in vivo study, only a mild protective effect of monoHER against 
oxidative stress was seen. As mentioned above, this may be related to the relatively 
low level of oxidative stress and relatively large variation in the lipid peroxidation 
marker (Figure 1A) because the onset of pathology was examined. An additional 
reason for this mild protection is that monoHER is administered once a day, whereas 
the half-life of monoHER is only half an hour (Abou El Hassan et al., 2003). Most 
of the time, monoHER will be practically absent (Jacobs et al., 2011), and for full 
protection by radical scavenging the compound has to be present continuously at a 
relatively high concentration. Scavenging of radicals at moments when 
concentrations of monoHER are relatively high, can explain the subtle effect of 
monoHER administration on oxidative stress. In addition, as mentioned above, the 
scavenging of radicals and the concurrent formation of the thiol-reactive oxidation 
product can selectively activate the innate NRF2 machinery. As demonstrated 
previously, a single and acute exposure to a thiol-alkylating agent can induce an 
adaptive response (Levonen et al., 2014; Sthijns et al., 2014; Wakabayashi et al., 
2004). This would mean that in order for monoHER to induce an adaptive response, 
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only part of the radicals needs to be scavenged since this already leads to the 
formation of the thiol-alkylating oxidation product of monoHER. 
 
Flavonoids have therapeutic potential in NAFLD which relates to their protection 
against oxidative stress. Our study supports a modified mechanism of action of the 
antioxidant flavonoid monoHER, which might also apply for other free radical 
scavenging antioxidants, as illustrated in Figure 2. The results show that the direct 
scavenging of radicals is only one aspect of protection by monoHER. The present 
study shows that activation of the antioxidant defense system (i.e. the activation of 
NRF2) by the oxidized flavonoid also plays a crucial role in the protective effect 
against oxidative stress (i.e. the improved GSH/GSSG ratio). This molecular 
mechanism does not only result in a very potent antioxidant effect, it also ensures 
that monoHER will act selectively in a condition of oxidative stress. In this way 
monoHER empowers the buffering capacity of the body to maintain homeostasis 
and to prevent that relatively mild but nevertheless insidious and persistent 
perturbations gradually progresses into a severe pathology, such as NAFLD. 
 
 
Figure 2. Overview of the protective effect of monoHER in the onset of NAFLD in mice. The 
high and therefore non selective reactivity of ROS results in damage to virtually any cellular 
compound. This oxidative damage is a hallmark in the etiology of NAFLD. ROS also activate 
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NRF2 which leads to adaptation. By scavenging the ROS, oxidation products of monoHER 
are formed that promote the adaptation of the cell to oxidative stress. This helps to maintain 
homeostasis and prevents that relatively mild perturbations gradually progress into a severe 
pathology such as NAFLD. 
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Supplemental data 
 
Table 2. Biometric data of mice. Initial and final body weight, body weight change, liver 
weight, liver/total body weight-ratio, average food intake of WT and Ldlr-/- mice treated with 
placebo (p) or monoHER. Mean ± SD is shown. 
 WT  
p 
WT 
monoHER 
Ldlr-/-  
p 
Ldlr-/- 
monoHER 
Initial body weight (g) 20.8±1.3 20.9±1.1 20.9±1.1 21.0±1.0 
Final body weight (g) 21.3±1.5 21.5±1.2 21.3±1.5 20.8±1.5 
Body weight change (g) 0.4±0.7 0.6±1.1 0.4±1.2 -0.1±0.8 
Liver weight (g) 1.00±0.14 1.01±0.10 1.05±0.12 1.04±0.11 
Liver/total body weight-
ratio (%) 
4.69±0.40 4.69±0.32 4.95±0.35 4.92±0.34 
Average food intake 
(g/day/cage) 
4.0 (0.3) 4.1 (0.3) 4.3 (0.3) 4.4 (0.3) 
 
 
 Effect on NAFLD 
89 
References 
 
2009. What is health? The ability to adapt. Lancet 373, 781. 
Abou El Hassan, M.A., Kedde, M.A., Zwiers, U.T., Tourn, E., Haenen, G.R., Bast, A., van 
der Vijgh, W.J., 2003. Bioavailability and pharmacokinetics of the cardioprotecting 
flavonoid 7-monohydroxyethylrutoside in mice. Cancer Chemotherapy and Pharmacology 
52, 371-376. 
Bast, A., Haenen, G.R., 2013. Ten misconceptions about antioxidants. Trends in 
Pharmacological Sciences 34, 430-436. 
Berlanga, A., Guiu-Jurado, E., Porras, J.A., Auguet, T., 2014. Molecular pathways in non-
alcoholic fatty liver disease. Clinical and Experimental Gastroenterology 7, 221-239. 
Bieghs, V., Van Gorp, P.J., Wouters, K., Hendrikx, T., Gijbels, M.J., van Bilsen, M., Bakker, 
J., Binder, C.J., Lutjohann, D., Staels, B., Hofker, M.H., Shiri-Sverdlov, R., 2012. LDL 
receptor knock-out mice are a physiological model particularly vulnerable to study the 
onset of inflammation in non-alcoholic fatty liver disease. PLoS One 7, e30668. 
Bruce, K.D., Sihota, K.K., Byrne, C.D., Cagampang, F.R., 2012. The housekeeping gene 
YWHAZ remains stable in a model of developmentally primed non-alcoholic fatty liver 
disease. Liver International 32, 1315-1321. 
Haenen, G.R.M.M., Bast, A., 1983. Protection against lipid peroxidation by a microsomal 
glutathione-dependent labile factor. FEBS letters 159, 24-28. 
Itoh, K., Tong, K.I., Yamamoto, M., 2004. Molecular mechanism activating Nrf2-Keap1 
pathway in regulation of adaptive response to electrophiles. Free Radical Biology and 
Medicine 36, 1208-1213. 
Jacobs,  H.,  Peters,  R.,  den Hartog,  G.J.,  van der Vijgh,  W.J.,  Bast,  A.,  Haenen, G.R.,  2011. 
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(beta-
hydroxyethyl)-rutoside in mice. Drug Metabolism and Disposition 39, 750-756. 
Julicher, R.H., Sterrenberg, L., Haenen, G.R., Bast, A., Noordhoek, J., 1988. The effect of 
chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. 
Archives of Toxicology 61, 275-281. 
Koek, G.H., Liedorp, P.R., Bast, A., 2011. The role of oxidative stress in non-alcoholic 
steatohepatitis. Clinica Chimica Acta 412, 1297-1305. 
Lemmens, K.J., Sthijns, M.M., van der Vijgh, W.J., Bast, A., Haenen, G.R., 2014a. The 
antioxidant flavonoid monoHER provides efficient protection and induces the innate Nrf2 
mediated adaptation in endothelial cells subjected to oxidative stress. PharmaNutrition 2, 
69-74 
Lemmens, K.J., van de Wier, B., Vaes, N., Ghosh, M., van Zandvoort, M.A., van der Vijgh, 
W.J., Bast, A., Haenen, G.R., 2014b. The flavonoid 7-mono-O-(beta-hydroxyethyl)-
rutoside is able to protect endothelial cells by a direct antioxidant effect. Toxicology in 
Vitro 28, 538-543. 
Lepage, G., Munoz, G., Champagne, J., Roy, C.C., 1991. Preparative steps necessary for the 
accurate measurement of malondialdehyde by high-performance liquid chromatography. 
Analytical Biochemistry 197, 277-283. 
Levonen, A.L., Hill, B.G., Kansanen, E., Zhang, J., Darley-Usmar, V.M., 2014. Redox 
regulation of antioxidants, autophagy, and the response to stress: implications for 
electrophile therapeutics. Free Radical Biology and Medicine 71, 196-207. 
Rolo, A.P., Teodoro, J.S., Palmeira, C.M., 2012. Role of oxidative stress in the pathogenesis 
of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 52, 59-69. 
Sthijns, M.M., Randall, M.J., Bast, A., Haenen, G.R., 2014. Adaptation to acrolein through 
upregulating the protection by glutathione in human bronchial epithelial cells: the 
Chapter 5 
90 
materialization of the hormesis concept. Biochemical and Biophysical Research 
Communications 446, 1029-1034. 
van Acker, S.A., Kramer, K., Grimbergen, J.A., van den Berg, D.J., van der Vijgh, W.J., Bast, 
A., 1995. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced 
cardiotoxicity. British Journal of Pharmacology 115, 1260-1264. 
van de Wier, B., Koek, G.H., Bast, A., Haenen, G.R., 2014. The potential of flavonoids in the 
treatment of non-alcoholic fatty liver disease. Critical Reviews in Food Science and 
Nutrition., in press. 
Wakabayashi, N., Dinkova-Kostova, A.T., Holtzclaw, W.D., Kang, M.I., Kobayashi, A., 
Yamamoto, M., Kensler, T.W., Talalay, P., 2004. Protection against electrophile and 
oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor 
modified by inducers. Proceedings of the National Academy of Sciences of the United 
States of America 101, 2040-2045. 
 
 
  
Chapter 6 
 
The contribution of the major metabolite  
4’-O-methylmonoHER to the antioxidant activity 
of the flavonoid monoHER 
 
Kristien J. A. Lemmens, Pauline M. Herst, Bas A.C. Housmans, Wim J.F. van der 
Vijgh, Aalt Bast, Guido R.M.M. Haenen 
 
Chapter 6: The contribution of the 
major metabolite 4’-O-methyl 
monoHER to the antioxidant 
activity of the flavonoid 
monoHER 
 
 
Chapter 6 
92 
Abstract 
 
The antioxidant flavonoid 7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) 
effectively protects against doxorubicin-induced cardiotoxicity in mice. Doxorubicin 
is a very effective anticancer drug. The clinical use of doxorubicin is limited by 
severe cardiotoxicity. Free radicals play a crucial role in this toxicity.  
In this study the involvement of the major metabolite of monoHER, 4’-O-
methylmonoHER (methylmonoHER) in the protective effect of monoHER is 
studied. MethylmonoHER displayed antioxidant activity i.e. TEAC, hydroxyl and 
superoxide radical scavenging activity; nevertheless monoHER appeared to be 
superior  compared  to  methylmonoHER.  As  a  result  of  scavenging,  flavonoids  are  
oxidized and display reactivity towards thiols. Oxidized methylmonoHER, is far less 
thiol reactive towards creatine kinase than monoHER, which indicates that 
methylmonoHER is less toxic towards thiol containing enzymes. The thiol-reactivity 
of oxidized methylmonoHER was also negligible towards KEAP1 compared to 
monoHER. These results indicate that methylmonoHER hardly protects against 
radical damage via scavenging or via activating the NRF2 defense system. Also in 
HUVECs, methylmonoHER provided far less protection against oxidative stress 
(EC50 > 100 µM) than monoHER which was a very potent protector (EC50 = 80 nM). 
The results indicate that the contribution of methylmonoHER to the protection 
against doxorubicin-induced cardiotoxicity by monoHER is relatively low. 
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Introduction 
 
Doxorubicin is an indispensable anticancer agent. However, the severe cardiotoxic 
effects limit the use of doxorubicin (Lipshultz et al., 2005). The formation of free 
radicals plays a crucial role in this toxicity (Horenstein et al., 2000; Xu et al., 2001). 
The heart is vulnerable because its antioxidant capacity is relatively low (Julicher et 
al., 1988). Therefore, antioxidants which scavenge or prevent the formation of free 
radicals were selected to provide protection. The proof of this concept is that the 
semisynthetic antioxidant flavonoid 7-mono-O-(ȕ-hydroxyethyl)-rutoside 
(monoHER) effectively protects against doxorubicin-induced cardiotoxicity in mice 
(van Acker et al., 1995).  
Our knowledge on the mode of action of antioxidant flavonoids has drastically 
increased. For several flavonoids it is known that metabolites of these flavonoids 
contribute to their effect (Ruijters et al., 2013). In this respect, much attention is 
given to O-methylated metabolites that are more readily taken up than the parent 
flavonoid, have an improved metabolic stability and display biological activity 
(Steffen et al., 2008), as demonstrated for the 4’-O-methyl metabolite of quercetin 
(Spencer et al., 2003). Similarly, a  contribution of the 4’-O-methyl metabolite to the 
overall effect of monoHER has been suggested (Jacobs et al., 2011). 4’-O-
methylmonoHER (methylmonoHER) is the major metabolite of monoHER and the 
AUC  and  Cmax of methylmonoHER in mice are higher than those of monoHER 
(Jacobs et al., 2011). This prompted us to study the antioxidant activity of this 
metabolite. 
In this study the 4’-O-methylated metabolite of monoHER was synthesized and its 
antioxidant activity was evaluated and compared to that of monoHER. Besides the 
potency to scavenge radicals, the channeling of the reactivity of the oxidized product 
towards proteins was studied. 
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Material and methods 
 
Chemicals 
7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER) was kindly provided by Novartis 
Consumer Health (Nyon, Switzerland). 2-Deoxy-D-ribose, ferric chloride 
hexahydrate (FeCl3.6H2O), ascorbic acid, dimethylformamide (DMF), diethyl ether, 
methyl iodide, sodium bicarbonate (NaHCO3), 2',7'-dichlorofluorescein-diacetate 
(DCFH-DA), and silica gel were purchased from Sigma (St. Louis, USA). H2O2 was 
obtained from Riedel-de Haën (Seelze, Germany). 2-thiobarbituric acid (TBA) and 
EDTA was purchased from Merck (Darmstadt, Germany). 2,2ƍ-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS), ammonium bicarbonate (ABC), 
acetonitrile (ACN), Į-cyano-4-hydroxycinnamic acid and trifluoroacetic acid (TFA) 
were obtained from Sigma (St. Louis, MO, USA). Azobisamidinepropane (ABAP) 
was purchased from Polysciences Inc. (Warrington, UK).  
 
Synthesis of 4’-O-methylmonoHER 
MonoHER was methylated with an excess of methyl iodide and 22 equivalents 
NaHCO3 dissolved in DMF. The reaction mixture was stirred at room temperature 
overnight. 
Under these circumstances the 4’-OH is mainly methylated. The product was 
extracted with diethyl ether. The crude product was purified by column 
chromatography on silica gel using a gradient of ethanol/toluene. The purity was 
confirmed using HPLC analysis. MethylmonoHER was identified by 1H and 13C 
NMR (Supplemental material). 
 
Hydroxyl radical scavenging assay 
In the assay, the scavengers, monoHER or methylmonoHER, are in competition 
with deoxyribose for a reaction with hydroxyl radicals. The hydroxyl radicals are 
formed in the reaction between Fe2+ and H2O2. Iron is kept in the reduced form by 
ascorbic acid. 
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The reaction mixtures contained 0-0.1 mM monoHER or methylmonoHER, 2.8 mM 
deoxyribose, 100 µM ascorbic acid and 2.8 mM H2O2 in 20 mM KH2PO4/K2HPO4 
buffer pH 7.4. Hydroxyl radical formation was started by adding 200 µl of a solution 
containing 20 µM FeCl3 and 0-100 µM EDTA in deoxygenated water. The mixture 
was incubated at 37 °C, and after 1 h 2 ml of a solution, containing 0.5 % TBA and 
1.4 % TCA was added. Subsequently, the mixture was heated at 100 °C for 20 min. 
The test tubes were cooled to room temperature. The absorbance (A) of the reaction 
mixture was measured at 532 nm. By plotting the reciprocal of the relative 
absorbance against the concentration of the scavenger, the apparent reaction rate 
constant (ks) of the reaction between the scavenger and the hydroxyl radicals was 
calculated according to (Haenen et al., 1993). 
 
Superoxide radical scavenging assay 
The superoxide radical scavenging activity of monoHER and methylmonoHER was 
determined according to Den Hartog et al. (den Hartog et al., 2003). Superoxide 
radicals were generated by xanthine 0.1 mM and xanthine oxidase 10 mU/mL. The 
radicals were detected by using nitroblue tetrazolium (NBT; 50 ȝM). The EC50, the 
amount of scavenger required to achieve an NBT reduction by a 50 % decrease, was 
determined. 
 
Total antioxidant capacity (TEAC) assay  
ABTS radical solution was prepared by heating (70 °C) a solution of ABTS (1.23 
mg/mL) and ABAP (3.96 mg/mL) in 50 mM phosphate buffer pH 7.4 for 20 min. 
50 ȝl of 0-20 µM monoHER or 0-50 µM methylmonoHER was added to 950 ȝl of 
the ABTS radical solution. After 5 min of incubation at 37 °C, the absorption at 
734 nm was measured. The decrease in absorption after 5 min relative to blank 
(buffer)  was  related  to  that  of  Trolox.  The  TEAC value  gives  the  concentration  of  
trolox that has a similar antioxidant capacity as the sample. 
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Reaction of oxidized monoHER or methylmonoHER with GSH 
To obtain an equal rate of oxidation (5 µM/min) monoHER and methylmonoHER 
(50 µM) were oxidized by 50 µM H2O2 and 1.6 or 128 nM HRP, respectively in a 
145 mM phosphate buffer pH 7.4, at 37 °C. If present, the concentration of GSH 
was  50  µM.  The  reaction  was  monitored  by  high-performance  liquid  
chromatography (HPLC) as previously described by Jacobs et al., 2010 (Jacobs et 
al., 2010). HPLC analysis was performed on a HP 1100 series HPLC system 
(Agilent Technologies, Palo Alto, USA) using a Supelcosil LC 318 reversed-phase 
column (5 µm, 25 cm x 4.6 mm) (Supelco, Bellefonte, USA). The mobile phase 
consisted of water with linear gradients of acetonitrile, containing 0.1 % (v/v) TFA. 
MonoHER and methylmonoHER were detected with a diode array detector at 355 
nm. 
 
Creatine Kinase activity 
MonoHER and methylmonoHER quinones were generated in situ by oxidizing the 
flavonoids (50 µM) with 50 µM H2O2 and 1.6 or 128 nM HRP respectively, in the 
presence of 6.2 µM creatine kinase (CK) in a 145 mM potassium-phosphate buffer 
pH 7.4. The reactions were started by adding the HRP and carried out at 37 °C for 5 
min.  
Enzyme activity of CK in the reaction mixtures was measured by the catalytic 
conversion  of  ADP  into  ATP.  Hexokinase  was  used  to  convert  ATP  with  glucose  
into glucose-6-phosphate. Finally, the glucose-6-phosphate formed converts NAD+ 
into NADH in the presence of glucose-6-phosphate dehydrogenase.  
The formation of NADH was measured spectrophotometrically at 340 nm during 5 
min representing the CK activity.  
 
Mass spectrometry 
MonoHER and methylmonoHER (50 µM) were oxidized by 50 µM H2O2 and 1.6 
or128 nM HRP in the presence of 0.5 mg/ml KEAP1 or 6.2 µM CK in 50 mM ABC 
buffer pH 7.4 for 15 min at 37 ÛC. KEAP1 was digested by trypsin during 2 hours at 
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37 ° C. CK was digested for 30 min. The digested samples were diluted 1:10 in 0.1 
% TFA. After dilution, 1 µl of the digest and 1 µl of matrix solution (2.5 mg/ml Į-
cyano-4-hydroxycinnamic acid in 50% ACN/0.1% TFA) was spotted on a 348-well-
format target plate and air-dried. Mass spectra were measured on a MALDI-TOF 
mass spectrometer (4800 MALDI-TOF analyzer; Applied Biosystems). The 
instrument was operated in positive reflector mode. Acquisition mass range was 
800-3500 Da. 
 
Cell culture 
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in T75 coated 
culture flasks (Greiner Bio-one, Alphen a/d Rijn, The Netherlands) in Ham’s F12-K 
medium (Invitrogen, Breda, The Netherlands) supplemented with 10 % (v/v) fetal 
calf serum (FCS; Invitrogen, Breda, The Netherlands), 0.05 mg/ml endothelial cell 
growth supplement (ECGS; BD Science, Franklin Lakes, USA), 1 % pen/strep 
(Gibco, Bleiswijk, The Netherlands) and 0.01 mg/ml heparin (LEO Pharma, 
Ballerup, Denmark) in a humidified atmosphere containing 5 % CO2 and 95 % air at 
37 °C. The maximal passage used was 20 in the measurement of intracellular 
oxidative stress. 
 
Measurement of intracellular oxidative stress 
The intracellular levels of oxidative stress were quantified by the fluorescence of 
dichlorofluorescein (DCF). The probe used has broad specificity; it detects H2O2, 
hydroxyl radicals, superoxide and other reactive species. 
Cells (4 X 104 per well) were plated out in a 96-wells plate (Greiner Bio-one, 
Alphen a/d Rijn, The Netherlands) 24 h before the experiment. The cells were then 
incubated with 20 µM DCFH-DA in 5 % CO2 and 95 % air at 37 °C for 45 min. 
After the medium with excess of DCFH-DA was removed, the cells were rinsed 
once with HBSS and subsequently incubated with 200 µM H2O2 and  0-1  µM  
monoHER or 0-100 µM methylmonoHER in serum-free medium. The fluorescence 
(Ex 485 nm, Em 538 nm) was determined on a microplate reader (Spectramax 
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microplate reader, Molecular devices, Sunnyvale, USA) as a measure of oxidative 
damage. 
The EC50, the concentration of monoHER or methylmonoHER which reduces 
intracellular oxidative stress by 50 % after 45 min, was determined by plotting the 
logarithm of the concentration of monoHER or methylmonoHER against the 
protection  (in  %)  at  time  point  45  min.  The  EC50 of monoHER was estimated by 
linear interpolation between the concentration 0.01 µM and 0.1 µM. 
Measurement of DCF in the medium revealed that in none of the incubations DCF 
leakage occurred (data now shown). 
The reaction of monoHER or methylmonoHER with H2O2 was examined by HPLC 
and spectrophotometrically (data not shown). Both compounds did not react with 
H2O2.   
 
LUMO map 
The software program Spartan ’06 (Wavefunction, Irvine, CA, USA) was used to 
generate the lowest unoccupied molecular orbital (LUMO) maps of simplified 
oxidized monoHER and oxidized methylmonoHER. 
 
Statistics 
All experiments were performed at least in triplicate. Data are expressed as mean ± 
standard deviation (SD). Statistical analysis was performed using Student’s t-test.  
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Results  
 
Radical scavenging activity 
Hydroxyl radical scavenging activity 
The apparent second order reaction rate constant (ks) of the reaction of monoHER 
with the hydroxyl radicals, was 240 X 108 M-1s-1 (Figure 1), which is similar to 
previously reported values (Lemmens et al., 2014b). The ks of methylmonoHER 
obtained was 110 X 108 M-1s-1. 
Omitting the chelator EDTA from the reaction mixture, increased the observed 
scavenging potency of monoHER threefold, whereas it had no effect on the 
scavenging potency of methylmonoHER (Figure 1). 
 
 
Figure 1. Determination of the hydroxyl radical scavenging activity of monoHER and 
methylmonoHER using a competition assay with deoxyribose. The deoxyribose concentration 
is 2.8 mM. The concentration of the scavenger is plotted on the x-axis. To determine the 
scavenging activity of monoHER and methylmonoHER, the breakdown products formed in 
the reaction of deoxyribose with OH-radicals were measured spectrophotometrically. 
MonoHER and methylmonoHER compete with deoxyribose for the OH-radicals and the 
presence of these compounds reduces the concentration of deoxyribose breakdown product. 
The absorbance obtained in the presence of monoHER or methylmonoHER (A) was related to 
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the absorbance obtained without these compounds (A0) which is a measure of the scavenging 
activity. Three independent experiments were performed and data are shown as mean ± SD. 
The apparent reaction rate (ks) of the reaction of monoHER and methylmonoHER with 
hydroxyl radicals with or without ETDA is shown in the insert (B). Data are shown as mean ± 
SD (n=3). * p<0.05, ** p<0.01 vs monoHER with and without EDTA, respectively. 
 
Superoxide radical scavenging activity 
The EC50 of monoHER in the superoxide radical scavenging assay was 22 µM. The 
EC50 of methylmonoHER was higher than 100 µM (Figure 2). Trolox had an EC50 of 
295 µM. 
 
 
Figure 2. Superoxide radical scavenging activity and Trolox Equivalent Antioxidant 
Capacity (TEAC-) values of monoHER and methylmonoHER. Superoxide radicals were 
spectrophotometrically detected by NBT. The reciprocal of the EC50,  the  amount  of  
monoHER and methylmonoHER required to achieve a 50 % NBT reduction, was shown.  
The TEAC-value is the decrease in absorption caused by monoHER and methylmonoHER, 
related to that of Trolox. Data are shown as mean ± SD (n=3). 
 
Antioxidant capacity (TEAC) 
MonoHER  had  a  TEAC  value  of  3.6  ±  0.6  mM.  MethylmonoHER  had  a  TEAC  
value  of  0.3  ±  0.1  mM (Figure  2).  Trolox is  used  to  calibrate  the  assay  and has  a  
TEAC of 1. 
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Reaction of the oxidized antioxidant 
Reactivity towards GSH 
HPLC analyses show that oxidation of monoHER and methylmonoHER by HRP 
and H2O2 leads to the consumption of monoHER and methylmonoHER at a rate of 
about 5 µM/min (Figure 3A and B). In the presence of GSH a new peak eluted at an 
identical position of the GSH-monoHER adduct (Figure 3C), confirming previous 
observation (Jacobs et al., 2009). Oxidation of methylmonoHER in the presence of 
GSH did result in a GSH-adduct (Figure 3C). 
 
Figure 3. HPLC analysis of 50 µM monoHER and methylmonoHER and of the incubation 
mixture containing 50 µM monoHER or methylmonoHER (A), with 50 µM H2O2 and 1.6 nM 
HRP or 128 nM HRP, respectively (B). The incubations were also carried out in the presence 
of 50 µM GSH (C).  The different incubation mixtures were injected on the HPLC system 5 
minutes after addition of HRP. The chromatograms are detected at 355 nm. A typical example 
is shown. The retention times of monoHER and methylmonoHER were 7.5 min and 8.5 min, 
respectively.  
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Reactivity towards proteins 
Reactivity towards CK and KEAP1  
MonoHER and methylmonoHER were oxidized in the presence of CK. Oxidized 
monoHER was found to reduce CK activity (25%). Oxidized methylmonoHER did 
not change the activity of CK (Figure 4). Control experiments revealed that 
methylmonoHER and monoHER when not oxidized, did not inhibit CK. 
MonoHER oxidized in the presence of CK reduced the intensity of the peak of the 
native peptide fragment, GYTLPPHCSR with a mass of m/z = 1131 measured by 
MALDI-TOF (peptide sequences were determined by the PeptideMass program via 
the ExPASy World Wide Web server). Instead, a new peptide fragment with a mass 
of m/z = 1783 emerged (Figure 4).  
MonoHER oxidized in the presence of KEAP1 reduced the intensity of the peak of 
the native peptide fragment, LNSAECYYPER with a mass of m/z = 1346. Instead, a 
new peptide fragment with a mass of m/z = 1997 emerged (Figure 5). 
The increment of the mass of the fragments corresponds to the molecular weight of 
the quinone of monoHER (652 Da). This indicates that the quinone formed by the 
oxidation of monoHER adducts CK and KEAP1. 
MethylmonoHER did not show an adduct with CK or KEAP1 (Figure 4 and 5). 
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Figure 4. Reactivity of monoHER and methylmonoHER towards CK. MALDI-TOF 
analysis of CK incubated with 50 µM monoHER or methylmonoHER, 1.6 nM or 128 nM 
HRP  and  50  µM  H2O2 for  5  min  at  37ÛC.  After  trypsin  digestion  the  mass  spectrum  of  
digested CK was measured. The control spectrum of CK displayed a peak at m/z 1131 and no 
peak at m/z 1783. The incubation with monoHER showed a peak at m/z 1783 which 
corresponds to the mass of the adduct of monoHER quinone (652 dalton) with the peptide 
having mass m/z 1131, whereas the peak at m/z 1131 decreased. The incubation with 
methylmonoHER did not show alterations in the peaks. 
The inserts show the effect of oxidized monoHER and methylmonoHER on the enzyme 
activity of CK. MonoHER and methylmonoHER (50 µM) were oxidized by 50 µM H2O2 and 
HRP, at an equal rate of oxidation (5 µM/min) in the  presence of 6.2 µM CK. The enzyme 
activity  of  CK  was  expressed  as  percentage  of  the  control.  Data  are  shown  as  mean  ±  SD       
(n = 3). 
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Figure 5. Adduction of KEAP1 by oxidized monoHER and by oxidized methylmonoHER. 
MALDI-TOF analysis of isolated KEAP1 (0.1 mg/ml) incubated with 50 µM monoHER or 
methylmonoHER, 1.6 or 128 nM HRP and 50 µM H2O2, after trypsin digestion. The control 
spectrum of KEAP1 displayed a peak at m/z 1345 and no peak at m/z 1997. The incubation 
mixture with monoHER showed a peak at m/z 1997 which corresponds to the mass of the 
adduct of the monoHER quinone (652 Da) on the peptide with mass m/z 1345, whereas the 
peak at m/z 1345 decreased. The incubation with methylmonoHER showed no new peaks. 
 
Protection against intracellular oxidative stress 
H2O2 added to HUVECs in a concentration of 200 µM, induced intracellular 
oxidative stress (Figure 6). Immediately after addition, monoHER protected 
HUVECs against the intracellular oxidative stress. The EC50 of monoHER after 45 
min was 80 nM. MethylmonoHER in a concentration of 100 µM mildly protected 
against intracellular oxidative stress. The EC50 of methylmonoHER after 45 min was 
higher than 100 µM. In none of the incubations, significant LDH leakage was 
observed (data not shown). 
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Figure 6. The effect of monoHER and methylmonoHER on the intracellular oxidative stress 
induced by 200 µM H2O2 in human umbilical vein endothelial cells. For the basal level, no 
H2O2 was used. Intracellular oxidative stress was measured using DCF fluorescence as 
described in the materials and methods section. A typical example is shown. In the insert (B) 
the oxidative stress after 45 min is shown. Three independent experiments were performed in 
triplicate and data are shown as mean ± SD (significantly lower than 0 µM flavonoid 
*p<0.001). 
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Discussion 
 
MonoHER protects against doxorubicin-induced cardiotoxicity in mice (van Acker 
et al., 2000). In this protective effect, metabolites of monoHER may be involved 
(Jacobs et al., 2011). In the present study the primary metabolite, methylmonoHER 
was examined. This metabolite was synthesized, and the antioxidant activity of the 
metabolite was determined and compared to that of the parent compound, 
monoHER. 
In the TEAC, superoxide and hydroxyl radical scavenging assay methylmonoHER 
was less potent than monoHER. It has been reported that the high hydroxyl radical 
scavenging activity of monoHER is due to its ability to chelate iron. This results in 
site-specific scavenging of radicals (Lemmens et al., 2014b). The hydroxyl radical 
scavenging assay shows that methylmonoHER is not able to site-specifically 
scavenge the hydroxyl radicals, indicating that methylmonoHER lacks the iron 
chelating ability of monoHER. 
The difference in the scavenging activity observed between monoHER and the 4’-O-
methylated metabolite can be explained by a higher electron donating effect of the 
aromatic 4’-OH group in monoHER than the O-methyl group in methylmonoHER. 
Several studies have also demonstrated that methylation of one of the OH-groups of 
the catechol containing antioxidants (the B ring of monoHER contains a catechol 
group) decreases the hydroxyl radical-, superoxide radical- and peroxynitrite 
scavenging activity (Rietjens et al., 2007). The importance of the 4’-OH for the 
intrinsic antioxidant activity has also been demonstrated for quercetin derivatives 
(Moalin et al., 2011).  
In their reaction with radicals, the antioxidant flavonoids are oxidized. These 
oxidized compounds are less reactive than the radicals they scavenged. In this way 
the reactivity becomes more selective by converting the non-selective reactivity of 
radicals into a relatively selective thiol reactivity of the oxidized flavonoid. Reaction 
of these oxidized flavonoids with reactive thiols of essential proteins results in 
cellular toxicity (Boots et al., 2002; Ito et al., 1988). The reactivity of oxidized 
monoHER towards thiols, e.g. GSH, is well described and also takes place in vivo. 
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Thus, a GSH-monoHER adduct was detected in vivo in the bile of healthy 
volunteers who received monoHER by intravenous infusion (Jacobs et al., 2009). 
Our results confirm the reactivity of oxidized monoHER towards GSH and CK an 
enzyme containing crucial cysteine groups. CK is important for energy production in 
cells. Inhibition of CK aggravates the energy crisis, which can finally lead to cell 
death (Reddy et al., 2000). With the use of MALDI-TOF, an adduct between 
oxidized monoHER and the enzyme was demonstrated. In addition, the enzyme 
activity of CK was attenuated by oxidized monoHER. This illustrates the potential 
thiol toxicity of monoHER.  
The other side of the coin of the thiol reactivity of oxidized monoHER is that it can 
also induce an adaptive response, because it can adduct reactive thiol groups on 
KEAP1.  The  adduction  of  KEAP1  sets  the  NRF2  machinery  in  motion,  which  
regulates the production of endogenous antioxidant enzymes (Itoh et al., 2004). In 
this way the thiol reactivity of oxidized monoHER is advantageous, because it leads 
to the enforcement of the cellular defense system.  
The thiol reactivity of oxidized methylmonoHER was also investigated. 
Interestingly, it was found that oxidized methylmonoHER did not inhibit CK. It also 
did not react with GSH or KEAP1. Apparently, the methylation of monoHER at 4’-
O drastically reduces the thiol reactivity of its oxidation product. 
The difference between monoHER and methylmonoHER in directing the reactivity 
of their oxidation products can be explained by Pearson’s HSAB concept (Pearson, 
1963). The Lowest Unoccupied Molecular Orbital (LUMO) of oxidized 
methylmonoHER is localized only in the B-ring and oxidized methylmonoHER 
contains a positively charged group that has a relatively high polarity (Figure 7). 
This results in a high LUMO energy which makes it a hard electrophile. Hard 
electrophiles react with hard nucleophiles. Oxidized methylmonoHER will therefore 
not react with thiols because they have a soft nucleophilic character. 
Oxidized monoHER is a softer electrophile than oxidized methylmonoHER. The 
LUMO of oxidized monoHER is distributed over the B-ring and part of the C ring 
which results in a relatively lower LUMO energy (Figure 7). Nevertheless, oxidized 
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monoHER will also prefer to pass its reactivity to hard nucleophiles but because of 
its relatively softer character it also has affinity for thiols. 
 
 
Figure 7. Structure and Lowest Unoccupied Molecular Orbital (LUMO) localization map of 
oxidized monoHER and methylmonoHER. The LUMO of oxidized monoHER is not 
completely distributed over the phenolic rings but only the B and part of the C rings, which 
explains why it behaves as a hard electrophile. The LUMO of oxidized methylmonoHER is only 
focused in the B-ring and oxidized methylmonoHER has a positive charge, which makes it an 
even harder electrophile compared to monoHER. 
 
In the cell experiment monoHER, at very low concentrations, was able to fully 
protect HUVECs against oxidative stress induced by H2O2. This probably involves 
the site specific scavenging activity. MonoHER can also indirectly protect against 
oxidative stress because the thiol reactive oxidation product - which is formed 
during the scavenging of radicals - is able to activate the NRF2 system by reacting 
with KEAP1. The activation of the NRF2 antioxidant defense system will give rise 
to an adaptive response (Lemmens et al., 2014a).  
 
MethylmonoHER, even at a concentration much higher than that of monoHER, 
could not offer direct protection in the HUVECs against oxidative stress. This is in 
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line with the poor scavenging activity of methylmonoHER. Due to the poor 
scavenging activity, hardly any oxidation product will be formed. In addition, the 
oxidation product of methylmonoHER does not react with KEAP1. This suggests 
that methylmonoHER will not boost the NRF2 antioxidant defense system.  
The present study shows that the intrinsic antioxidant effect of methylmonoHER is 
less than that of monoHER, which means that despite of its relatively high Cmax and 
AUC, the contribution of methylmonoHER to the protection against doxorubicin-
induced cardiotoxicity is relatively low. 
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Abstract 
 
MonoHER is a semisynthetic flavonoid, derived from the naturally occurring 
flavonoid rutin, and has beneficial health effects. MonoHER has shown protective 
effects in diseases in which oxidative stress plays an important role. Its antioxidant 
properties are involved in the protection. Besides its antioxidant activities monoHER 
also has anti-inflammatory properties which can be advantageous in the protection 
of disorders in which inflammation is an important factor. The multitude of 
physiological effects prompted us to review the mechanisms and processes behind 
the health effects of monoHER.  
Because of the beneficial effects, monoHER could be used in the treatment of 
several diseases. We conclude that monoHER is a nutraceutical that forms a bridge 
between nutrition and drugs. 
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Introduction 
 
In ancient cultures, there was no clear difference between nutrition and drugs. This 
is probably best illustrated by the adage of one of the founders of medicine, 
Hippocrates: “Let food be thy medicine and medicine be thy food”. In the 20th 
century, the idea evolved that drugs and nutrition are separate entities. A drug 
became  a  synthetic  compound  that  was  carefully  designed  to  effectively  cure  a  
specific disease. Nutrition was regarded as a source of energy, building blocks and 
essential nutrients, like vitamins, that need to be consumed in sufficient amounts to 
prevent deficiencies. In the last decades our knowledge on the health effect of 
nutrition has tremendously increased and the gap between drugs and nutrition closes 
down again.  
The group of nutritional compounds in the spotlight, for quite some time, is the 
flavonoids. This group, that comprises over 5000 different compounds, is 
abundantly present in plant derived foodstuffs. A wealth of data indicates that the 
regular intake of flavonoids has a beneficial effect on chronic disorders, including 
cardiovascular diseases and neurodegenerative disorders and possibly even cancer. 
Flavonoids may display prophylactic as well as curative effects, or alleviated 
pathological symptoms. In this way this group of so called “nutraceuticals” 
illustrates the closing of the gap between nutrition and drugs. 
This review focusses on the nutraceutical, 7-mono-O-(E-hydroxyethyl)-rutoside 
(monoHER). MonoHER is a semisynthetic flavonoid and is a constituent of 
Venoruton, a registered drug that is used in the treatment of chronic venous 
insufficiency. Venoruton also contains other structurally related 
hydroxyethylrutosides (HERs), i.e. diHER, triHER and tetraHER. These HERs are 
derived from the flavonoid rutin by substituting its hydroxyl groups with O-ȕ-
hydroxyethyl  groups.  Of  the  HERs,  monoHER  appeared  to  be  the  most  powerful  
antioxidant (Haenen et al., 1993; van Acker et al., 1993).  
This review addresses the health effects of the flavonoid monoHER and its possible 
use as a nutraceutical.  
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Chemical characterization 
 
MonoHER is formed by chemically modifying the naturally occurring flavonoid 
rutin, abundantly present in Buckwheat. In the synthesis of monoHER, a 
hydroxyethyl group is linked to the oxygen at the 7- position in the A ring of rutin 
(Figure 1). The hydroxyethyl groups were introduced to improve the water 
solubility, which was regarded as rate limiting factor in the biological effect of the 
nutritional compound. 
Like most flavonoids, monoHER consists of three rings referred to as the A, B and 
C  rings  (Figure  1).  The  basic  structure  of  monoHER  is  similar  to  the  structure  of  
quercetin; it contains an ortho-dihydroxy group in the B ring (catechol), and a C2-
C3 double bond and 4-oxo function in the C ring. MonoHER also contains a 
rutinose group (glucose + rhamnose) at the 3-O position in the C ring.  
 
 
Figure 1. Structural formula of the nutraceutical monoHER. It consists of a nutrient (rutin) 
build up by quercetin and rutinose, which is chemically modified by the chemical addition of 
a hydroxyethyl group. 
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Bioavailability and pharmacokinetics  
 
Before a compound can exert a systemic effect, it first has to be taken up. The 
bioavailability and pharmacokinetics of monoHER in mice has been studied after 
different routes of administration. The levels of monoHER in plasma and heart were 
also measured. 
After oral administration to mice, no monoHER could be detected in plasma of 
mice,  indicating  that  monoHER  has  a  very  poor  oral  bioavailability.  The  oral  
bioavailability was estimated to be less than 1 % (Abou El Hassan et al., 2003a). 
After intravenous (i.v.), intraperitoneal (i.p). and subcutaneous (s.c.) administration, 
monoHER could be detected in plasma and in the heart. After administration the 
maximal concentration is reached relatively quickly and after the peak the 
concentration decreases rapidly. MonoHER could not be detected for longer than 2 
hours  after  i.v.,  i.p.  or  s.c.  administration   (Abou  El  Hassan  et  al.,  2003a).  After  
administration of labeled monoHER, radioactivity was measured in plasma for at 
least 6 h when radiolabeled monoHER was administered. It was suggested that the 
HERs of Venoruton® (including  monoHER)  are  taken  up  in  the  vascular  wall  
(Neumann et al., 1992). Neumann et al. found that these flavonoids were localized in 
the endothelial and sub-endothelial layer of varicose long saphenous veins after i.v. 
administration. Recently, it was found that monoHER was retained in the wall of the 
carotid arteries of mice after i.p. administration, more specifically in the nucleus 
(Lemmens et al., 2014a; Lemmens et al., 2014c). 
The bioavailability after i.p. administration was 30%, after s.c. administration 40%. 
The pharmacokinetics of monoHER were determined (Table 1). I.p. administration 
of monoHER (500 mg/kg) showed a maximal concentration (Cmax) of 131 µM and 
35.3 µM in plasma and heart, respectively after 5-15 min. MonoHER disappeared 
from the plasma and heart tissue with a half-life (t1/2) of about 30 min. The area 
under the curve (AUC)  was  6.3  µmol  min/  ml  in  plasma (Abou El  Hassan  et  al.,  
2003a).  
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Toxicity studies of monoHER in several animal models revealed neither acute, nor 
chronic toxic effects nor teratogenic effects after oral administration of monoHER 
(Berte, 1974; Chesterman et al., 1973; Davies and Collins, 1973a, b, c; Hunter et al., 
1973; Lueschner, 1974). To evaluate the possible side effects of monoHER and to 
investigate the pharmacokinetics of monoHER in men, a phase I clinical trial was 
performed (Willems et al., 2006). The study was performed as a single blind, 
randomized trial in healthy volunteers. MonoHER was administered as an i.v. 
infusion in 10 minutes. MonoHER was dissolved in 5% dextrose and the pH was 
adjusted to 8.4. Up to 1500 mg/m2 (equal to a dose of approximately 3 gram per 
volunteer) monoHER was well-tolerated and no serious side-effects were observed. 
At this dose, a mean peak plasma concentration of 360 ± 69 ȝM and a mean AUC 
of 6.8 ± 2.1 ȝmol min/ml, which is equal to mice administered i.p. with 500 mg/kg 
monoHER, were obtained (Table 2). MonoHER was still detectable in plasma after 
8 hours. The data also showed that monoHER is rapidly distributed and eliminated 
from the plasma compartment, which corresponds with a rapid uptake in and 
elimination from heart tissue as found in mice. From this phase I study, it could be 
concluded that 1500 mg/m2 of monoHER is a safe dose to be used in further clinical 
studies (Willems et al., 2006). 
 
Table 1. Summary of the pharmacokinetic parameters of monoHER in plasma and heart 
tissue of mice treated with 500 mg/kg i.v., i.p. and s.c (Abou El Hassan et al., 2003a). 
 i.v. i.p. s.c. 
pK paramaters Plasma Heart Plasma Heart Plasma Heart 
Cmax (nmol/ml) 2 X 103 0.4 X 103* 131 35.3* 229.3 68.4* 
tmax(min) 0 0 5-15 5-15 10-20 10 
t1/2final (min) 11.8 16.2 28.5 25.7 23.9 29.3 
AUC (µmol min/ml) 24.7 5.6* 6.3 1.6* 8.0 2.0* 
AUC0-120min (µmol min/ml) 20.5 4.9* 6.1 1.6* 8.0 2.0* 
MRT (min) 10.9 12.1 43.6 43.0 34.1 41.5 
* Expressed per gram wet tissue 
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Table 2. Summary of the pharmacokinetic parameters of monoHER in plasma of healthy 
volunteers treated with 1500 mg/m2 i.v. (Willems et al., 2006). 
 i.v. 
pK paramaters Plasma 
Cmax (nmol/ml) 360 ± 69 
t1/2Į (min) 5.0 ± 1.6 
t1/2ȕ (min) 27 ± 11 
t1/2ܵ (min) 168 ± 148 
AUC (µmol min/ml) 6.8 ± 2.1 
MRT (min) 33.4 ± 8.8 
 
The metabolism of monoHER was investigated in mice (Jacobs et al., 2011c). 
MonoHER was mainly excreted via bile in feces (Barrow and Griffiths, 1971, 1974; 
Hackett and Griffiths, 1977), therefore the metabolism was determined in the bile 
fluid. Thirteen different metabolites were characterized. The observed routes of 
monoHER metabolism were methylation, glucuronidation, oxidation of its 
hydroxyethyl group, GSH conjugation, and hydrolysis of its disaccharide (Figure 2).  
The metabolism of monoHER was also investigated in the bile fluid of healthy 
volunteers (Jacobs et al., 2011b). The same metabolites were found in humans as 
previously in mice. However, the relative amounts of the metabolites were quite 
different (Figure 2). The major metabolic route in mice appeared to be methylation 
while in men especially glucuronidation was observed.  
 
 
Chapter 7 
120 
 
Figure 2. Proposed metabolism of monoHER in mice and men. The percentages which are 
not underlined indicate the relative amounts of each metabolite in mice (Jacobs et al., 2011c). 
The underlined percentages indicate the relative amounts of each metabolite in men (Jacobs et 
al., 2011b). 
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Molecular mechanisms 
 
Radical scavenging 
MonoHER is an effective radical scavenger. It scavenges a wide variety of radicals; 
hydroxyl, superoxide radicals (Haenen et al., 1993; Lemmens et al., 2014c). This 
excellent scavenging can be traced down to several structural elements. The catechol 
moiety in the B ring and the C2-C3 double bond and 4-oxo function in the C ring 
contribute to the scavenging activity of monoHER (van Acker et al., 1996). During 
scavenging, monoHER is oxidized by the radical, and the oxidized monoHER is 
relatively stable due to delocalization of the free electron over the ʌ-system. 
 
Iron chelation 
In addition to the radical scavenging, monoHER also has the ability to chelate iron. 
The result of this chelation is that monoHER is present at the site of the radical 
formation, i.e. the iron ion. This enables monoHER to immediately scavenge the 
newly formed radical (van Acker et al., 1998). This ‘site-specific scavenging’ is 
essential for its excellent hydroxyl radical scavenging activity.  MonoHER 
scavenges OH-radicals at an extremely high reaction rate - ks = 980 X 108 M-1s-1 - 
which is, remarkably, even quicker than the diffusion rate (~ 100 X 108 M-1s-1).   
By this site-specific scavenging, monoHER is able to prevent damage to critical 
biomolecules such as lipids, proteins or DNA, despite the high reactivity of the 
radical. 
 
Adaptation 
Oxidized monoHER, which is formed after scavenging radicals, is reactive itself. 
However, the reactivity of the oxidized product is less reactive and thus more 
selective than the radical. Oxidized monoHER can channel reactivity towards thiols, 
evidenced by the formation of a GSH-monoHER adduct after monoHER 
administration to human volunteers (Jacobs et al., 2009). It has been reported that 
oxidized monoHER adducts KEAP1, which functions as an in vivo sensor for ROS 
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and electrophiles (Lemmens et al., 2014a). By reacting with KEAP1, the Nuclear 
factor erythroid 2-related factor 2 (NRF2) endogenous antioxidant defense system is 
activated. NRF2 dissociates from the KEAP1-NRF2 complex and translocates to the 
nucleus. NRF2 binds to antioxidant response elements (ARE) in the promoter region 
of genes encoding various antioxidants and phase II detoxifying enzymes e.g. heme 
oxygenase-1 (HO-1), glutathione peroxidases (Gpx), superoxide dismutase (SOD). 
MonoHER itself does not activate the NRF2 system because it lacks the thiol 
reactivity. In this way monoHER induces an adaptive response in cells exposed to 
oxidative stress (Figure 3). MonoHER empowers the buffering capacity of the body 
to maintain homeostasis and to prevent that relatively mild but nevertheless 
insidious and persistent perturbations gradually progress into a severe pathology 
(Lemmens et al., 2014a). 
 
 
Figure 3. Overview of the protective effect of monoHER against ROS toxicity and the 
induction of the adaptive response of the cell. MonoHER protects by scavenging the ROS. 
The oxidized monoHER formed during scavenging selectively adducts KEAP1 and activates 
the NRF2 pathway (Lemmens et al, 2014a). 
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Protein binding 
The thiol reactivity of oxidized monoHER can also lead to enzyme inhibition. 
Oxidized monoHER can react with critical thiol groups of a protein which will lead 
to function loss. 
 
Health effects of monoHER 
 
MonoHER has already been applied in the treatment of several diseases. Its 
beneficial health effects are reviewed separately. The involvement of the various 
molecular mechanisms and processes in the health effects is depicted in Figure 4. 
 
 
Figure 4. Schematic overview of the molecular mechanisms and processes involved in the 
beneficial health effects of monoHER. (NRF2: Nuclear factor erythroid 2-related factor 2, 
CBR1: carbonyl reductase 1, CML: Nİ-(carboxymethyl) lysine, NF-țB: nuclear factor-țB, 
NAFLD: Non-alcoholic fatty liver disease) 
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Vascular diseases 
In chronic venous insufficiency oxidative stress plays an important role. Venoruton, 
the rutin mixture containing monoHER, is used in the treatment of chronic venous 
insufficiency for over several decades. 
It has also been shown that monoHER has antioedematous properties in rats by 
inhibiting the action of bradykinine, histamine and carrageenin (Lecomte and Van 
Cauwenberge, 1974). Moreover, monoHER showed antithrombotic effects 
(Hladovec, 1977a; Mirkovitch, 1977). It prevented endothelial injury caused by 
nicotine and citrate (Hladovec, 1977b, 1978), it increased skin capillary resistance in 
a rat model (Gabor, 1981) and reduced microvascular permeability in frogs (Kendall 
et al., 1993). 
 
NAFLD 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in 
Western countries. One of the hallmarks in the etiology of NAFLD is oxidative 
stress  (Koek  et  al.,  2011;  Rolo  et  al.,  2012).  MonoHER  has  shown  to  be  a  potent  
protector against NAFLD in mice by inducing an adaptive response (Lemmens et 
al., 2014b). MonoHER induces the NRF2 pathway and enforces the endogenous 
antioxidant shield, to provide protection against NAFLD.  
 
ȕ-thalassemia 
ȕ-thalassemia is an autosomal blood disorder caused by mutations in the gene 
encoding ȕ-globin, resulting in reduced or absent ȕ-chain synthesis of hemoglobin. 
This leads to an excessive body iron store which will result in the formation of free 
radicals. Oxidative damage plays a significant role in the premature destruction of 
erythrocytes in thalassemias (Origa and Galanello, 2011). 
As an effective radical scavenger and iron chelator, monoHER treatment of ȕ-
thalassemic mice resulted in substantial improvements in several parameters related 
to membrane oxidative stress and lipid peroxidation (de Franceschi et al., 2004). 
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Doxorubicin-induced cardiotoxicity 
Because of its excellent iron chelating and radical scavenging properties (Lemmens 
et al., 2014c), monoHER was tested as a protector against doxorubicin-induced 
cardiotoxicity. Doxorubicin is a very effective antitumor agent, but its clinical use is 
limited by the occurrence of a cumulative dose-related cardiotoxicity, resulting in 
congestive heart failure (Bast et al., 2007; Lipshultz et al., 2005; Singal and 
Iliskovic, 1998). Doxorubicin-induced cardiotoxicity presumably results from free 
radicals, which are produced during redox-cycling of doxorubicin (Horenstein et al., 
2000; Julicher et al., 1988; Xu et al., 2001). MonoHER protected almost completely 
(92.7%) against doxorubicin-induced cardiac damage in an isolated atrium model 
(van Acker et al., 1993). In mice, cardioprotection was observed when monoHER 
was administered as an intraperitoneal (i.p.) dose of 500 mg/kg five times/week in 
combination with a weekly intravenously (i.v.) dose of 4 mg/kg doxorubicin for a 
period of six weeks (van Acker et al., 1995). A single i.p. injection (500 mg/kg) of 
monoHER only once a week 1 hour before doxorubicin administration (4 mg/kg, 
i.v.) also gave complete protection (van Acker et al., 2000) (Figure 3). 
Both in vitro and in vivo, monoHER protected against the toxic effect of doxorubicin 
on cardiac cells without interfering with the cytostatic effect on cancer cells (van 
Acker et al., 1997).  
To unravel the mechanism underlying the selective protective effects of monoHER, 
it was investigated whether monoHER (1 mM) affects doxorubicin-induced 
apoptosis in neonatal rat cardiac myocytes (NeRCaMs), human umbilical vein 
endothelial cells (HUVECs) and the ovarian cancer cell lines A2780 and OVCAR-3. 
The data indicated that monoHER might act by suppressing the activation of 
molecular mechanisms that mediate either caspase-dependent or -independent cell 
death (Bruynzeel et al., 2007b). However, the concentration of monoHER needed (1 
mM) indicates that the in vitro inhibition of the antitumor effect of doxorubicin is 
not relevant for the clinical application of monoHER. 
The time interval between monoHER and doxorubicin did not show a significant 
change in protection against doxorubicin-induced cardiac damage (Bruynzeel et al., 
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2006). Abou El Hassan et al.  showed that the cardioprotection observed in mice is 
not caused by a pharmacokinetic interaction between monoHER and doxorubicin. 
 
Some studies suggest that inflammation induced by doxorubicin plays a role in its 
cardiotoxic effects (Deepa and Varalakshmi, 2006; Hecker, 1990; Hou et al., 2005). 
To investigate whether doxorubicin could induce an inflammatory response in vitro, 
HUVECs were incubated with increasing concentrations of doxorubicin. 
Doxorubicin affected both the viability and proliferation capacity of endothelial cells 
(Abou El Hassan et al., 2003b). Doxorubicin also increased the adhesion of 
neutrophils, which was accompanied by the overexpression of VCAM and E-
selectin. MonoHER was able to protect against these doxorubicin-induced 
inflammatory effects (Abou El Hassan et al., 2003b) (Figure 5).  
 
 
Figure 5. Overexpression of VCAM 25 h after incubation with doxorubicin. The combined 
treatment with monoHER prevented the concentration-dependent doxorubicin-induced 
overexpression of the adhesion molecule (Abou El Hassan et al., 2003b) 
 
In addition, in vivo, it was demonstrated by Bruynzeel et al. that treatment with 
doxorubicin induces an increase of Nİ-(carboxymethyl) lysine (CML) in 
intramyocardial arteries in mice (Bruynzeel et al., 2007a). The induced increase in 
CML, which is regarded as a biomarker for local endogenous stress, was found to be 
reduced by the anti-inflammatory agents, ketoprofen and dexamethasone, and by 
monoHER. These findings confirm the role of inflammation in doxorubicin-induced 
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cardiotoxicity and indicate that monoHER has - besides its antioxidant activity, 
radical scavenging and iron chelating properties - anti-inflammatory properties 
which could also be involved in the protection against cardiac damage.  
 
The cardioprotective effect of monoHER could also be explained by the inhibition 
of the enzyme carbonyl reductase 1 (CBR1). The enzyme reduces doxorubicin into 
the metabolite doxorubicinol which is more cardiotoxic than the parent compound. 
 
By promoting the antioxidant defense, the heart is able to adapt against oxidative 
stress caused by doxorubicin. The involvement of an adaptive response in the 
protection against doxorubicin-induced cardiotoxicity by monoHER should further 
be investigated. 
 
The possible involvement of the major metabolite 4’-O methylmonoHER was 
studied (Lemmens et al., 2015). It was concluded that the antioxidant activity of 
monoHER drastically decreased after methylation at 4’-O position which indicates 
that the contribution to the protective effect by the metabolite is relatively low.  
 
Based on the promising results with monoHER observed in preclinical experiments, 
a phase II study was performed to investigate the cardioprotective effect of 
monoHER on doxorubicin-induced cardiotoxicity in cancer patients (Bruynzeel et 
al., 2007c). MonoHER did not significantly protect against doxorubicin- induced 
cardiotoxicity in these cancer patients. The dose should be further investigated. 
 
Ischemia 
The anti-inflammatory effect of monoHER was also observed in a study on 
ischemia-reperfusion injury in mice. Inflammation and oxidative stress play a crucial 
role in the ischemia-reperfusion injury. The monoHER treatment significantly 
attenuated myocardial neutrophil influx and significantly reduced infarct size after 
reperfusion (De Celle et al., 2004). 
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Cancer 
The effect of monoHER on the antitumor activity of doxorubicin was observed in 
the clinical phase II study (Bruynzeel et al., 2007c). An intriguing observation was 
that three of the four patients diagnosed with soft tissue sarcomas experienced 
objective remissions, while the fourth had stable disease. This 75% response rate is 
much higher than the expected remission of approximately 25% (Santoro et al., 
1995). It is therefore suggestive that monoHER enhances the antitumor activity of 
doxorubicin in soft tissue sarcomas.  
The effect of monoHER on the enhancement of the antitumor activity of 
doxorubicin was investigated in vitro, in a soft tissue sarcoma cell line. 
Chemotherapeutic agents are known to induce the transcription factor nuclear factor-
țB (NF-țB), which causes drug resistance in cancer cells. MonoHER prevented the 
induction of NF-țB by doxorubicin in soft tissue sarcoma cell line, WLS-160 
(Jacobs et al., 2011a). In this way cancer cells are sensitized to doxorubicin via the 
down-regulation of the NF-țB activation by monoHER. MonoHER may also be 
valuable in the treatment of other tumors that are resistant via NF-țB activation. 
 
Other pharmacological properties of monoHER 
Several other pharmacological properties of monoHER have been described. It has 
also been shown that monoHER has an effect on enzymes that intervene in the 
metabolism of mucopolysaccharides in human and bovine veins. The presence of 
monoHER (1 mg/ml) inhibited the enzyme ȕ-glucuronidase extracted from human 
veins for 12.5% and for 70.3% when extracted from bovine veins, while monoHER 
did not significantly influence the activity of the enzyme N-acetylglucosaminidase 
obtained from both veins (Niebes and Laszt, 1971). MonoHER also affected 
prostaglandin synthesis in guinea pig lung tissue and human skin (Gosta, 1973).  
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Future research 
 
The protective effect of monoHER against the cardiotoxicity induced by 
doxorubicin is still enigmatic. In the future the involvement of metabolites in the 
protective effect should further be investigated as well as the adaptive response. 
 
Conclusion 
 
MonoHER a derivative of rutin, a natural flavonoid present in food, has versatile 
beneficial health effects. Besides his antioxidant activity, monoHER also has anti-
inflammatory and anti-tumor properties. It was shown that monoHER can support 
the body to adapt to endogenous or exogenous threats. Because of these beneficial 
effects, monoHER can be used in the treatment of several diseases. We can conclude 
that monoHER is a nutraceutical that forms a bridge between nutrition and drugs. 
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Flavonoid intake is associated with beneficial health effects. The antioxidant activity 
plays a crucial role in the protective action of flavonoids (chapter 1).  The  aim of  
this thesis was to further elaborate on the molecular mechanism of the antioxidant 
effect of flavonoids. The focus was put on the antioxidant, flavonoid 7-mono-O-(ȕ-
hydroxyethyl)-rutoside (monoHER), quercetin and their 4’-O-methyl metabolites. 
 
The flavonoid monoHER is a potent protector against cardiotoxicity induced by 
doxorubicin. The potential relevance of the direct scavenging activity of monoHER 
was studied in chapter 2. 
MonoHER protected against intracellular oxidative stress in human umbilical vein 
endothelial cells (EC50 =  60  nM),  which  confirmed  the  involvement  of  a  direct  
scavenging activity by therapeutically achievable concentrations. This direct effect 
of monoHER was due to its perfect location on three levels. On a molecular level, 
monoHER is located at the site of radical formation where it site-specifically 
scavenges the radical involved. On a biochemical level, monoHER is located at a 
pivotal position in the antioxidant network. On a cellular level, monoHER is located 
in the endothelial and smooth muscle cells in the vascular wall.  
This explains that monoHER displays a physiologically important direct antioxidant 
effect. 
 
When ROS are scavenged, they take up an electron or a hydrogen atom from the 
antioxidant flavonoid. In this way the reactive species are neutralized. In contrast, 
the flavonoid is oxidized and becomes reactive itself. The reactivity of the oxidized 
flavonoid is less than that of the radical scavenged which makes it more selective. 
Flavonoids are reported to selectively channel the reactivity towards thiol groups. 
Hence, oxidized flavonoids may threat vital cellular compounds containing a critical 
thiol group.  
In chapter 3 the thiol reactivity of the antioxidant flavonoid quercetin was compared to 
that of 4’-O-methylquercetin (tamarixetin) towards creatine kinase (CK), a vital 
protein that contains a critical thiol moiety. Oxidized quercetin and oxidized 
tamarixetin are reactive towards CK; both oxidized flavonoids adducted the enzyme, 
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which led to the loss of its function. Oxidized tamarixetin was less thiol toxic than 
oxidized quercetin, because - rather than adduction to CK - oxidized tamarixetin 
prefers to pass reactivity to the antioxidant network, i.e., to ascorbate. Apparently, a 
small structural modification such as the introduction of a methyl group has a great 
influence on the channeling of the reactivity.  
When oxidized flavonoids channel their reactivity toward the thiol containing 
protein  KEAP1,  this  leads  to  adaptation  (chapter 4). In chapter 4 the effect of 
antioxidant flavonoid monoHER on the cellular adaptive response in HUVECs 
exposed to H2O2 was studied. 
It was found that oxidized monoHER adducts KEAP1, which activates the NRF2 
antioxidant defense system. NRF2 is released from the KEAP1-NRF2 complex, 
translocates to the nucleus and upregulates the expression of antioxidant genes, e.g. 
of HO-1. In this way monoHER offers direct protection and induces adaptation 
against oxidative stress.  
Thiol reactivity can lead on the one hand to toxic effects by damaging cellular 
compounds - as demonstrated in chapter 3 - and on other hand to a beneficial 
adaptive response. As shown in chapter 4, monoHER added to cells subjected to 
oxidative stress protects against the damage but does not reduce the adaptive 
response to oxidative stress while no toxicity is observed. Apparently, the protective 
and adaptive effect of monoHER prevails over the possible toxicity.  
 
In chapter 5 the effect of monoHER on oxidative stress as well as the adaptive 
response in the onset of NAFLD in Ldlr-/- mice on a high-fat and high-cholesterol 
diet was studied. Wild type mice served as a control.  The effect of monoHER was 
compared to that of a placebo.  
In the Ldlr-/- group, no pronounced effect of monoHER against ROS damage was 
seen. This could be due to the relatively large variation in the results which is 
probably because the onset of the disease was studied. In the placebo Ldlr-/- group 
the NRF2 antioxidant defense system was activated, evidenced by a higher HO-1 
and Gpx3 gene  expression,  as  well  as  an  increased  redox status,  evidenced by the  
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higher GSH/GSSG ratio. MonoHER tended to further increase the HO-1 and Gpx3 
gene expression and the GSH/GSSG ratio in the Ldlr-/- group.  
Surprisingly, a strong within animal relationship was found that links a relatively 
low redox status to an improved NRF2 activation in the monoHER Ldlr-/- group. 
This correlation was absent in the placebo and wildtype group. Apparently, 
monoHER administration results in a relatively potent adaptation. Based on the 
concept developed in this thesis, this can be explained by the thiol reactivity of 
oxidized monoHER, formed after scavenging. Oxidized monoHER adducts the 
thiol-containing protein, KEAP1 and consequently stimulates the NRF2 system. In 
wildtype mice monoHER did not induce the adaptive response because monoHER 
itself lacks the thiol reactivity.  
From chapter 5 it was concluded that monoHER enforces the endogenous 
antioxidant shield, to provide protection against NAFLD. 
 
In chapter 6 the contribution of the major metabolite of monoHER, 4’-O-
methylmonoHER (methylmonoHER) to the protective antioxidant effect of 
monoHER was investigated.  
MethylmonoHER was synthesized and the antioxidant activity was evaluated and 
compared to that of monoHER. In the TEAC, hydroxyl and superoxide radical 
scavenging activity assays, methylmonoHER was far less potent than monoHER. 
The thiol reactivity of oxidized methylmonoHER was also less compared to that of 
monoHER; methylmonoHER was less reactive towards the thiol-containing proteins 
CK and KEAP1. These findings suggest that methylmonoHER hardly protects 
against radical damage via scavenging or via activating the NRF2 defense system. 
This was confirmed in HUVECs; monoHER which was a very potent protector 
(EC50 = 80 nM) whereas methylmonoHER provided minor protection against 
oxidative stress (EC50 > 100 µM). 
The results indicate that the involvement of methylmonoHER in the protection 
against doxorubicin-induced cardiotoxicity by monoHER is relatively low. 
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The pharmacological effects of monoHER and the potential use as a nutraceutical 
were reviewed in chapter 7. 
It was concluded that monoHER is a nutraceutical which has already been applied 
and of which the use can be extended in the treatment of diseases in which oxidative 
stress plays a crucial role. MonoHER directly protects against oxidative stress. In the 
direct protection against oxidative stress, monoHER is converted into a thiol reactive 
quinone. Interestingly, the thiol reactive quinone can adduct KEAP1 ultimately 
leading to an adaptive response. In this way the antioxidant monoHER selectively 
protects cells that are subjected to oxidative stress, which can be seen as an elegant 
way of targeting the protective effect of this nutraceutical. 
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Implications and future perspectives 
 
The research described in this thesis further unraveled the molecular mechanism of 
the protective effect of flavonoids i.e. monoHER, quercetin and their 4’-O-methyl 
metabolites. It was substantiated that flavonoids are able to protect against oxidative 
stress and also to promote an adaptive response. 
Subjects that are still open for research are: 
- the in vivo adaptive effect of monoHER 
- the molecular mechanism behind the anti-inflammatory effect of monoHER 
- the protection against doxorubicin-induced cardiotoxicity by metabolites 
other than 4’-O-methylmonoHER 
- the retention of monoHER and its metabolites in the nucleus of the 
endothelial cells 
- the thiol reactivity/toxicity and the channeling of the reactivity of other 
flavonoids 
- the protective and adaptive effects of other flavonoids 
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De inname van flavonoïden is geassocieerd met gezondheidsbevorderende effecten. 
De antioxidant activiteit speelt een grote rol in de beschermende werking van 
flavonoïden (hoofdstuk 1). Het doel van dit proefschrift is het verder ontrafelen van 
het moleculair mechanisme achter het antioxidant effect van flavonoïden. De 
antioxidant flavonoïden 7-mono-O-(ȕ-hydroxyethyl)-rutoside (monoHER), 
quercetine en hun 4’-O-methyl metabolieten werden bestudeerd. 
 
Het flavonoïd monoHER geeft effectieve bescherming tegen doxorubicine 
geïnduceerde cardiotoxiciteit. De potentiële relevantie van het directe effect van het 
wegvangen van radicalen door monoHER werd bestudeerd in hoofdstuk 2. 
MonoHER beschermt tegen intracellulaire oxidatieve stress in humane navelstreng 
veneuze endotheelcellen (HUVECs) (EC50 = 60 nM). Dit bevestigt de betrokkenheid 
van het directe effect van het wegvangen van radicalen bij therapeutisch haalbare 
concentraties. Dit directe effect van monoHER komt door de perfecte locatie op 3 
vlakken. Op moleculaire vlak is monoHER gelokaliseerd op de plaats waar radicalen 
gevormd worden. Op deze manier kan monoHER locatie-specifiek de radicalen 
wegvangen. Op biochemisch vlak bevindt monoHER zich op een gunstige plaats in 
het antioxidant netwerk. Op cellulair vlak situeert monoHER zich in endotheel- en 
gladde spiercellen van de veneuze wand. 
Dit verklaart waarom monoHER een fysiologisch belangrijk direct antioxidant effect 
vertoont in de vaten. 
 
Als de reactieve zuurstof deeltjes weggevangen worden, nemen zij een elektron of 
een waterstof atoom op van het antioxidant flavonoïd. Op deze manier worden de 
reactieve deeltjes geneutraliseerd. Daarentegen wordt het flavonoïd geoxideerd en 
zelf reactief. De reactiviteit van het geoxideerde flavonoïd is minder dan die van het 
weggevangen radicaal waardoor het selectiever wordt. Het is bekend dat flavonoïden 
selectief hun reactiviteit kanaliseren naar thiolgroepen. Daardoor kunnen 
geoxideerde flavonoïden een gevaar zijn voor fysiologisch belangrijke cellulaire 
moleculen die een thiolgroep bevatten. 
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In hoofdstuk 3 werd de thiolreactiviteit van het antioxidant flavonoïd quercetine 
vergeleken met die van 4’-O-methylquercetine (tamarixetine) ten opzichte van 
creatine kinase (CK), een cruciaal eiwit dat een belangrijke thiolgroep bevat. 
Geoxideerd quercetine en geoxideerd tamarixetine zijn reactief ten opzichte van CK; 
beide geoxideerde flavonoïden vormen een adduct met het enzym. Dit leidt tot het 
verlies in functie van het enzym. Tamarixetine was minder thioltoxisch dan 
quercetine omdat het geoxideerde tamarixetine liever zijn reactiviteit doorgeeft aan 
het antioxidant netwerk, i.e. vitamine C, dan een adduct te vormen met CK. 
Klaarblijkelijk heeft een kleine structurele modificatie, zoals het introduceren van 
een methylgroep, een groot effect op het kanaliseren van de reactiviteit. 
 
Als geoxideerde flavonoïden hun reactiviteit kanaliseren naar het thiolhoudende 
eiwit KEAP1, leidt dit tot adaptatie (hoofdstuk 4). In hoofdstuk 4 wordt het effect 
bestudeerd van de antioxidant monoHER op de cellulaire adaptieve respons in 
HUVECs blootgesteld aan H2O2. 
Er werd aangetoond dat monoHER een adduct vormt met KEAP1, dat vervolgens 
het NRF2 antioxidant beschermingssysteem activeert. NRF2 wordt vrijgemaakt uit 
het KEAP1-NRF2 complex, transloceert naar de kern en induceert de expressie van 
antioxidant genen, b.v. HO-1. Op deze manier biedt monoHER directe bescherming 
en induceert het adaptatie tegen oxidatieve stress. 
Thiolreactiviteit kan aan de ene kant leiden tot toxische effecten door het 
beschadigen van cellulaire componenten, zoals beschreven in hoofdstuk 3, en aan de 
andere kant tot een voordelige adaptieve respons. Zoals aangetoond in hoofdstuk 4, 
beschermt monoHER cellen blootgesteld aan oxidatieve stress tegen schade en 
reduceert het de adaptieve respons tegen oxidatieve stress niet terwijl er geen 
toxiciteit veroorzaakt wordt. Het beschermende en adaptieve effect via thiol 
adductvorming van monoHER treedt blijkbaar eerder op dan de mogelijke 
thioltoxiciteit. 
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In hoofdstuk 5 werd het effect van monoHER bestudeerd op de oxidatieve stress en 
de adaptieve respons in het beginstadium van NAFLD in Ldlr-/- muizen op een hoog 
vet en hoog cholesterol dieet. 
In de Ldlr-/- groep was er geen uitgesproken effect van monoHER op de schade door 
reactieve zuurstof deeltjes. Dit kan verklaard worden door de relatief grote variatie 
in de resultaten die waarschijnlijk veroorzaakt wordt doordat het beginstadium van 
de ziekte bestudeerd wordt. In de placebo Ldlr-/- groep werd het NRF2 antioxidant 
beschermingssysteem geactiveerd, aangetoond door een hogere HO-1 en Gpx3 
genexpressie en een verhoogde redox status, aangetoond door een hogere 
GSH/GSSG  ratio.  MonoHER  neigde  de  HO-1 en Gpx3 genexpressie en de 
GSH/GSSG ratio te verhogen in de Ldlr-/- groep. 
Opmerkelijk was dat er een sterke relatie werd gevonden tussen een lage redox 
status en een verhoogde NRF2 activatie in de monoHER Ldlr-/- groep. Deze 
correlatie was afwezig in de placebo en wildtype groep. Blijkbaar resulteert de 
toediening van monoHER tot een relatieve effectieve adaptatie. Gebaseerd op het 
concept ontwikkeld in dit proefschrift, kan dit verklaard worden door de 
thiolreactiviteit van het geoxideerd monoHER, gevormd na het wegvangen van 
radicalen. Geoxideerd monoHER vormt een adduct met het thiolhoudende eiwit, 
KEAP1 en vervolgens wordt het NRF2 systeem geactiveerd. In de wildtype muis 
induceerde monoHER de adaptieve respons niet omdat monoHER zelf die 
thiolreactiviteit niet bezit. 
Uit hoofdstuk 5 kan geconcludeerd worden dat monoHER het endogene 
antioxidantsysteem versterkt en op deze manier bescherming biedt tegen NAFLD. 
 
In hoofdstuk 6 werd de bijdrage van de belangrijkste metaboliet van monoHER, 4’-
O-methylmonoHER (methylmonoHER) aan het beschermende antioxidant effect 
van monoHER bestudeerd. 
MethylmonoHER werd gesynthetiseerd en de antioxidant activiteit geëvalueerd en 
vergeleken met die van monoHER. De TEAC-waarde van methylmonoHER was 
lager dan die van monoHER en ook in het wegvangen van hydroxyl en superoxide 
radicalen was methylmonoHER veel minder effectief dan monoHER. De 
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thiolreactiviteit van geoxideerd methylmonoHER was minder dan die van 
monoHER; methylmonoHER was minder reactief ten opzichte van de thiolhoudende 
eiwitten CK en KEAP1. Deze bevindingen suggereren dat methylmonoHER amper 
bescherming biedt tegen radicaalschade via het wegvangen en het activeren van het 
NRF2 beschermingssysteem. Dit werd bevestigd in HUVECs; monoHER biedt zeer 
effectieve bescherming (EC50 = 80 nM) tegen oxidatieve stress maar 
methylmonoHER gaf zeer weinig bescherming (EC50 > 100 µM). 
De resultaten wijzen erop dat de bijdrage van methylmonoHER in de bescherming 
tegen de doxorubicine geïnduceerde cardiotoxiciteit door monoHER gering is. 
 
De farmacologische effecten van monoHER en het potentiële gebruik als 
nutraceutical werd beschreven in hoofdstuk 7. 
Er werd geconcludeerd dat de nutraceutical monoHER reeds lange tijd wordt 
toegepast bij een groot scala aan ziektes waarin oxidatieve stress een belangrijke rol 
speelt. MonoHER biedt directe bescherming tegen oxidatieve stress. In deze directe 
bescherming ontstaat er een thiolreactief product. Dit thiolreactief product vormt een 
adduct met KEAP1 dat uiteindelijk leidt tot een adaptieve respons. Op deze manier 
beschermt de antioxidant monoHER selectief cellen die blootgesteld zijn aan 
oxidatieve stress. Dit kan gezien worden als een elegante manier van targeting van 
het beschermende effect van de nutraceutical.  
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Implicaties en verder onderzoek 
 
Het onderzoek beschreven in dit proefschrift ontrafelt het moleculaire mechanisme 
achter het beschermende effect van flavonoïden i.e. monoHER, quercetin en hun 4’-
O-methyl metabolieten. Er werd geconcludeerd dat flavonoïden bescherming 
kunnen bieden tegen oxidatieve stress en dat ze de adaptieve respons kunnen 
stimuleren. 
Interessante onderwerpen die nog verder onderzocht kunnen worden: 
- de adaptieve response van monoHER in vivo in de mens 
- het moleculaire mechanisme achter het anti-inflammatoire effect van 
monoHER  
- de bescherming tegen de doxorubicine geïnduceerde cardiotoxiciteit door 
andere metabolieten dan 4’-O-methylmonoHER 
- de retentie van monoHER en zijn metabolieten in de kern van 
endotheelcellen 
- de thiolreactiviteit/thioltoxiciteit en het kanaliseren van de reactiviteit van 
andere flavonoïden  
- het beschermende en adaptieve effect van andere flavonoïden  
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Radicalen behoren tot de meest reactieve verbindingen die in de cel worden 
geproduceerd. Ze kunnen reageren met alle moleculen in het lichaam zoals vetten, 
eiwitten en het DNA. Om zich te beschermen tegen deze schadelijke stoffen, heeft 
het lichaam een beschermingssysteem. Dit beschermingssysteem bestaat uit 
antioxidanten die de radicalen kunnen neutraliseren. Een teveel aan radicalen leidt 
tot schade die bepaalde ziekten, zoals leverziekten en neurodegeneratieve ziekten 
kan veroorzaken. 
De voeding vormt een rijke bron aan antioxidanten. Een belangrijke groep van 
antioxidanten in de voeding zijn de flavonoïden. Een flavonoïd rijk dieet beschermt 
tegen o.a. hart- en vaatziekten, chronische inflammatoire ziekten en kanker. 
Daarnaast kunnen flavonoïden, vooral in hoge dosering, ook schadelijk zijn.  
De precieze werking van deze flavonoïden is niet helemaal duidelijk. In dit 
proefschrift wordt deze werking verder onderzocht van de flavonoïden monoHER, 
quercetine en hun gemethyleerde metabolieten. Quercetine is een natuurlijk 
voorkomend flavonoïd dat wijdverspreid in de voeding voorkomt in o.a. uien en 
appels. Quercetine kan ook verkregen worden als supplement. MonoHER is een 
semi-synthetisch flavonoïd afkomstig van het natuurlijke flavonoïd rutine dat 
chemisch is aangepast om de stabiliteit en bioactiviteit te verhogen. 
Flavonoïden staan aan de top van de pikorde van antioxidanten. Zij vangen de 
radicalen als eerste in. Bij het wegvangen van de radicalen, geeft het flavonoïd een 
elektron of een waterstof-atoom aan het radicaal waardoor het radicaal 
geneutraliseerd wordt. Het flavonoïd wordt zelf geoxideerd en daardoor reactief. 
Deze reactiviteit is minder dan die van het radicaal maar selectief voor thiolgroepen 
van bv. eiwitten. Deze thiolgroepen zijn essentieel in de werking van eiwitten. 
Wanneer geoxideerde flavonoïden reageren met de thiolgroepen van eiwitten, zullen 
de functies van de eiwitten veranderen. Dit kan uiteindelijke leiden tot toxiciteit. 
Quercetine laat deze thiolreactiviteit duidelijk zien. Geoxideerd quercetine remt de 
activiteit van creatine kinase, een enzym belangrijk in de energielevering. 
Geoxideerd monoHER is ook thiolreactief maar in mindere mate. MonoHER 
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verkiest de reactiviteit door te geven aan vitamine C dan aan thiolen. Vitamine C is 
in staat om het monoHER te regenereren. 
De thiolreactiviteit van geoxideerd monoHER kan, naast schade, ook leiden tot 
adaptatie. Het geoxideerde monoHER activeert het antioxidant 
beschermingssysteem van het lichaam.  
MonoHER beschermt dus tegen de schade veroorzaakt door radicalen en zal er voor 
zorgen dat het lichaam zich aanpast aan de situatie waarin het zich bevindt. Dit kan 
gezien worden als een elegante manier van gerichte bescherming (‘targeting’). 
Het doorgeven van de reactiviteit speelt een belangrijke rol in de werking van 
flavonoïden. Bij het toedienen van een flavonoïd dient er gekeken te worden in 
welke richting de reactiviteit wordt doorgegeven. Bij quercetine lijkt dit meer 
richting toxiciteit te gaan, bij monoHER wordt duidelijk ook adaptatie gezien. Om 
gezondheidsbevorderende effecten van een flavonoïd te verkrijgen moet er een 
optimale balans gevonden worden tussen toxiciteit en adaptatie. 
 
Planning 
 
In de toekomst moet de antioxidantwerking van andere flavonoïden verder in kaart 
worden gebracht want elk flavonoïd is anders. Het doorgeven van de reactiviteit en 
de balans tussen toxiciteit en adaptatie zal hierbij betrokken moeten worden. Als de 
werking van flavonoïden gekend is, kunnen ze op een optimale manier ingezet 
worden in behandelingen van ziekten want elke ziekte zal om een ander flavonoïd 
vragen. Ons onderzoek maakt het mogelijk om het juiste flavonoïd te kiezen voor 
diverse aandoeningen. Met deze kennis kan de voeding in diverse klinische situaties 
aangepast worden of kunnen er juist ‘getargete’ geneesmiddelen op basis hiervan 
ontwikkeld worden. 
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Ik zou iedereen willen bedanken die geholpen heeft om dit boekje tot stand te 
brengen. Zonder jullie had ik het nooit gekund! 
Eerst en vooral een woord van dank aan mijn promotieteam, waaronder mijn 
promoter Prof. dr. Aalt Bast en copromotores Dr. Guido R.M.M. Haenen en Prof. dr. 
Wim J.F. van der Vijgh. 
Aalt, dankjewel voor de goede en enthousiaste begeleiding! De wekelijkse 
besprekingen waren zeer nuttig en inspirerend. Je stelde me altijd de vraag: ‘Wat 
willen we eigenlijk weten?’ waardoor ik door de bomen het bos weer zag. Bedankt 
dat je nooit je vertrouwen in mij bent verloren! 
Guido, bij jou is er nooit een drempel. Je staat altijd open voor vragen. Telkens wist 
je me weer te boeien. Je bent een echte ideeëngenerator. Bij het schrijven van dit 
boekje heb je me veel geholpen. Ik heb veel van je geleerd. Je bent een ‘reus’ en ik 
heb veel kunnen zien op je schouder. 
Ik ben jullie zeer dankbaar dat ik als postdoc kan beginnen. 
Wim, ik bewonder je onuitputtelijke interesse voor het onderzoek en de wetenschap. 
Onze ‘meander’-besprekingen samen met Aalt en Guido waren telkens zeer nuttig! 
Je zorgde ervoor dat we een goede planning opstelden. Mijn manuscripten bekeek je 
steeds heel gedetailleerd. Je kritische vragen hebben me vaak aan het denken gezet. 
Ook al zaten we niet vaak samen, ik heb erg veel van je opgestoken. Ik vind het leuk 
dat we tijdens mijn postdoc-project nog samen kunnen werken. 
 
Hartelijk dank aan de beoordelingscommissie voor het beoordelen van dit 
proefschrift. 
 
Vervolgens wil ik mijn super zus en grote voorbeeld bedanken. Sofie, door je eigen 
ervaring raadde je me aan om een baan te zoeken op de uni. Daardoor ben ik als 
laborant kunnen beginnen en verder opzoek gegaan naar een interessant 
promotieonderzoek. Ik heb veel bewondering voor alles wat je doet, en vooral hoe je 
het doet: precies, nauwkeurig, bedachtzaam,...  
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Ik heb deze AIO-positie in grote mate te danken aan jou, Daniëlle. Je duwde me 
letterlijk naar binnen bij Aalt. Bedankt voor je uitleg over celkweek, experimenten, 
het beantwoorden van mijn vragen maar ook de leuke uitstapjes buiten het werk. 
My paranymphs Agnieszka and Carmen! Thanks for the nice time at the 
department in our room. I could always talk to you about anything! Thanks for the 
support during my defense. Good luck with your own defenses! 
Bregje, jou wil ik vooral bedanken voor de leuke samenwerking tijdens de 
muizenstudie. Er is een interessante publicatie uit ontstaan, hoofdstuk 5. Je was een 
toffe collega! 
Leonie en Marie-Jose, ook aan jullie bedankt voor de hulp bij de muizenstudie en 
resultaten in hoofdstuk 6.  
Dankjewel Misha voor je leuke resultaten waaruit een mooi hoofdstuk (3) is 
gekomen. Samen met Roger B. en Leonie hebben jullie gezorgd voor super 
uitstapjes, fijne babbels en leuke sfeer. Bedankt!  
My other roommates Erik (dankjewel voor je hulp bij de experimenten, 
computerproblemen, het beantwoorden van al mijn vragen,…), Matt (thanks for the 
entertainment, especially the singing and gossips ;) ), Max (bedankt voor de de hulp 
bij de synthese van methylmonoHER) and Nuria (thanks for the nice chats). 
Dankjewel Hilde om mij het monoHER-project over te dragen.  
Rianne, Alie, Quan and Gesiele thank you for the nice time in the lab and beyond. 
Good luck with your defenses! 
Bedankt Roger B., Esther, Joy, Lou, Daniëlle P. en Marie-Jose voor de hulp bij 
de praktische zaken op het lab en de gezellige sfeer. 
Bedankt Marie-Claire voor het regelen van afspraken en de administratieve zaken 
maar ook de leuke praatjes. 
In die 4 jaar heb ik de kans gekregen om studenten te begeleiden. Nathalie, Arjan, 
Kelsey, Mireille, Katerina, Frederik, Pauline, Bas, bedankt voor jullie hulp. 
Hopelijk hebben jullie ook iets van mij kunnen leren.  
Bedankt Mitrajit, Marc, Jeroen voor de hulp bij de fluorescentiemetingen in de 
vaten en Freek voor de hulp bij de MALDI-TOF metingen. 
Dankwoord 
154 
Ik mocht paranimf zijn bij de promoties van Sofie, Max, Matt, Danielle, Erik 
dankjulliewel! Het was een hele eer! Thank you! I was honoured! 
Dankjewel aan Antje, Gertjan, Merel, Jiska, Roger G, Agnes, Geja, Thalita, 
Kimberly, Marieke, Frederik-Jan, Aggie, Edwin, Jan, Pieter en de collega’s van 
farmacologie voor de tips, fijne samenwerking en leuke sfeer. 
De (ex)collega’s van toxicogenomics: Lize, Sandra, Karen, Leen, Wim en Dennie 
bedankt voor de gezelligheid. 
Dankjewel Leo, Matty, Simone en Stijn dat ik als laborant ben kunnen starten op 
de uni.  
Chris, dankjewel voor het ontwerpen van de mooie cover en uitnodiging. 
Dank aan Maria, Simon, Caroline, Pieter, Jonathan en Robin voor jullie 
ondersteuning, goede zorgen en de ontspannende momenten.  
Mijn Mama en Papa, Sofie en Giel, ik kan de dankbaarheid amper uitdrukken in 
woorden. Jullie staan altijd klaar voor mij. Jullie toonden steeds veel interesse in 
mijn werk en hebben me steeds aangemoedigd. Dankjewel voor alle vertrouwen.  
Mijn liefje, Martijn. Je hebt me door dik en dun gesteund in deze hele periode. Je 
stelde me altijd gerust: ‘Het komt allemaal goed!’. Ik bewonder je geduld en 
relativeringsvermogen. Ik kijk uit naar meer tijd met jou samen in ons huisje. 
(Bedankt voor je hulp bij figuur 3 in hoofdstuk 2 ;) ) 
 
Bedankt iedereen voor de ondersteuning en hulp maar ook voor de super 
promotieperiode! 
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